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ABSTRACT 
MODELING HEART FAILURE PREDICTIVE MORTALITY IN SKILLED 
NURSING FACILITIES 
 
Stephen Biondi, MSN, RN 
 
Marquette University, 2020 
 
 
Problem: Approximately 25% of skilled nursing facility (SNF) patients are 
diagnosed with heart failure (HF). The heart failure mortality trajectory is non-linear and 
there are no useable mortality models from clinical records for use by healthcare 
providers in the SNF setting. A mortality risk model for patients with HF is important so 
that palliative care interventions may be offered to improve patients’ quality of life 
during the end stages of dying. Assessment items captured routinely by the SNF Resident 
Assessment Instrument –Minimum Data Set 3.0 (RAI-MDS) instrument may be useful in 
identifying those patients whose declining condition warrants discussion of palliative 
care. 
 
Methodology: Data from 1827 eligible HF patient’s RAI-MDS assessments, who 
resided in Midwest SNFs during 2013-14, were investigated in a retrospective cross-
sectional exploratory method. Discrete survival analysis and logistic regression were used 
to determine which factors predict mortality so as to allow future creation of a model to 
prompt palliative care discussions.  
 
Results: Nine variables embedded in the RAI-MDS were selected based upon a 
literature review of HF mortality prediction models. Five of the nine variables 
demonstrated predictive hazard ratios (HR) in the SNF setting. These included re-
admission after hospitalization (HR 1.323), reduced renal function (HR 1.187), presence 
of dyspnea (HR 1.285), age 85 and older (HR 1.828), and having three or more diagnoses 
(HR 1.345). Not predictive were having diagnoses of diabetes or hypertension, being 
sixty-five to eighty-four years of age, and gender.   
 
Conclusions: The mortality predictors identified in this study may facilitate 
development of a HF mortality risk model specific to patients in SNFs. Such a model 
may be useful in making decisions regarding when to institute palliative care discussions 
with SNF patients and their families. 
 
 
 
 
 
 
 
 
 
i 
 
 
ACKNOWLEDGEMENTS 
 
Stephen Biondi 
 
I am extremely grateful to have had the opportunity to continue to learn 
throughout my life and achieve a PhD in Nursing. Achieving this milestone was 
something that I had dreamed about for years. I am hopeful that having this increased 
knowledge and understanding of the nursing profession will allow me to continue to find 
ways to give back to my colleagues and advance th profession. 
I have many individuals that I wish to thank. Dr. Marilyn Meyer Bratt, my 
committee chair, who was there for me throughout this journey. She mentored me on the 
nuances of defining my study, writing effectively and efficiently, and kept me from 
losing my faith in my ability to achieve this goal. She was tireless in assisting me to be 
the best that I can and sacrificed many hours to lead me to a successful defense and study 
result. A sincere thanks to Dr. Marilyn Meyers Bratt! 
Dr. Donna McCarthy, Dr. Susan Breakwell, and Dr. Anna Nicolaou, my other 
committee members, were there with me throughout the entire process providing insight 
into how to strengthen my study and to effectively communicate the results. Each of 
these professional colleagues were tireless in finding the time and energy to assist me in 
making this study the best it could possibly be. Thank you for all that you did for me.  
Dr. Janet Krejci, Marquette University College of Nursing Dean, has been a 
mentor to me even prior to my entrance into the nursing profession. She has guided me in 
so many ways and continues to demonstrate courage, leadership, and compassion in all 
that she does. Thank you Dr. Krejci! 
Lastly, I would be remiss if I didn’t thank my life partner of 34 years, Don 
Schmitt, who was always there to encourage me, to prop me up when challenges arose, 
and who always believed in me. And to my mother, Joan, who was also a R.N. who 
inspired me to seek this degree. I hope that others may find the strength to continue to 
pursue their dreams and make this world a better place. Thank you to my colleagues and 
friends for the endless support to make this world a better place for all those in it.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii 
 
 
 
TABLE OF CONTENTS 
 
 
ACKNOWLEGEMENTS…………………………………………………………………i 
 
LIST OF TABLES………………………………………………………………...……..vi 
 
LIST OF FIGURES……………………………………………………………………...vii 
 
CHAPTER 
I. INTRODUCTION…………………………………………………………….1 
Background and Significance………………………………………..........1 
Heart Failure Mortality……………………………………………............2 
The Skilled Nursing Facility Heart Failure Patient…………………...…..5 
Palliative Care in the Skilled Nursing Facility…………………...…….....6 
Heart Failure Mortality Risk Models……………………………..……….7 
The SNF Minimum Data Set Assessment Instrument (RAI-MDS 3.0…....7 
Purpose and Aims of this Study……………………………………….…..8 
Significance to Nursing………………………………………………....…9 
Significance to Patients and Their Families……………………………...10 
Summary……………………………………………………….………...10 
II.  REVIEW OF THE LITERATURE………....……………………..………..11 
Philosophical Underpinnings and Conceptual Framework…….………...11 
Conceptual Model…………………………………………..……...…….12 
Philosophical Framework…………………...…………………………...14 
Literature Review…………………………………………...…..…….….17 
Heart Failure Risk Factors Identified…………..……..………….18 
iii 
 
Hypertension……………………………………...……………...18 
Diabetes Mellitus……………………………………...................19 
Obesity………………………………………...............................19 
Atherosclerotic Heart Disease………………………………...….20 
Other Etiological Risk Factors……………………….………......20 
Frailty………………………………………………………...…..20 
 Comorbid Diagnoses………………………………………...…..21 
Advanced Heart Failure……………………………….………....23 
Mortality and Hospitalization……………………….…...............24 
Age……………………………………………………………….24 
Gender……………………………………………………….…...25 
Risk Factor Conclusion……………………………..……………25 
Heart Failure Risk Models Compared and Contrasted…………..25 
Identification of Study Variables……………………………..….36 
Study Assumptions…………………………………………..…………..38 
Research Question and Aims………………………………...............…..39 
Gaps in the Literature………………………………………………....….40 
III. RESEARCH DESIGN AND METHODS………....…………...…………....41 
Dataset Quality…………………………………………....…………..….41 
Instrument Reliability and Validity: RAI-MDS 3.0………......................43 
Study Database……………………………………………………….......44 
Study Variables……………………………………………......................46 
Data Analytical Methodology and Procedures…………………………...48 
iv 
 
Methodological Rigor…………………………………….....…………...51 
IV. RESULTS…………………………………...………………………….........53 
Survival Analysis Model Results………………………….......................54 
Hospital Readmission……………………….……………………….......55 
Reduced Renal Function ………………………………………………...57 
Hypertension…………………………………………………………..…58 
Dyspnea………………………………………………...……………...…59 
Diabetes………………………………………………………………..…60 
Age 65 Plus……………………………………………………………....61 
Age 85 and Greater………………………………………........................62 
Gender………………………………………………………………....…63 
Three or More Diagnoses…………………………………………...…....64 
 
V. DISCUSSION……………………………………………………………......66 
Predictive Variables…………………………………..……………….…66 
   Hospital Re-Admission………………………..……………........66 
   Reduced Renal Function…………………….………………...…67 
   Dyspnea…………………………………………………………..68 
   85 Years Old and Older…………………………………...…..…69 
   Three or More Diagnoses…………………………………..…….69 
Non-Predictive Variables……………………………………………..….70 
 Hypertension………………………………………………….….70 
   Diabetes……………………………………………………….….71 
   Age 65 to 84……………………………………………….……..72 
   Gender……………………………………………………….…...72 
v 
 
  Theoretical and Practical Findings of Implications………………….…..73 
  Methodological, theoretical, and/or Statistical Importance of  
the Findings…………………………………………………………..…..74 
  Clinical Significance of the Findings……………………………….....…75 
Relationship between the Findings, Previous Research, and the 
Theoretical/Conceptual Framework/Model……………………....……...76 
   Implications of the Research for Nursing Practice,  
 
   Education, and Research…………………..……………………..………77 
 
   Implications for Vulnerability and Vulnerable  
   Populations………………………………………………………...……..79 
   Strengths and Weaknesses or Limitations of the Study……………….…79 
  Suggestions for Future Research…………………..………………….....80 
  Summary…………………………………………………………....……82 
BIBLIOGRAPHY…………………………………………………………...………...…83 
APPENDIX A……………………………………………………………………...…….92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
LIST OF TABLES 
 
 
 
TABLE 1.   
 
Heart Failure Mortality Risk Variables……………………………………….….92 
TABLE 2. 
 Number of Patients Alive vs. Death at 60, 90, 120, and 180 Days………………53 
TABLE 3 
 Model Results……………………………………………………………………54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
LIST OF FIGURES 
 
 
FIGURE 1 
 
 Conceptual Empirical Model of Heart Failure Mortality………………………..14 
 
FIGURE 2 
 
 Modeling Heart Failure………………………………………………………......51 
 
FIGURE 3 
 
 Hospital Readmission ……………………………………………………….…..56 
 
FIGURE 4 
 
 Survial Curve: Reduced Renal Function………………………………………....57 
 
FIGURE 5 
 
 Survival Curve: Hypertension…………………………………………………....59 
 
FIGURE 6 
 
 Survival Curve: Dyspnea…………………………………………………….…..60 
 
FIGURE 7 
 
 Survival Curve: Diabetes……………………………………………………..….61 
 
FIGURE 8 
 
 Survival Curve:  Age 65 to 84………………………...……………………..…..62 
 
FIGURE 9 
 
 Survival Curve: Age Greater than 85………………………………………...…..63 
 
FIGURE 10 
 
 Survival Curve: Gender……………………………………………………….....64 
 
FIGURE 11 
 
 Survival Curve: Three or More Diagnoses……………………………………....65
1 
 
Modeling Heart Failure Predictive Mortality in Skilled Nursing Facilities 
 
 
Chapter 1: Introduction 
 
Background and Significance 
 
Heart failure is a chronic debilitating terminal illness that affects over 5.1 million 
people in the United States, or about 2.1% of the population (Go et al., 2014; Mozaffarian 
et al., 2015; Yancy et al., 2013). There are 650,000 new cases diagnosed each year with 
prevalence increasing as the population ages. Heart failure is one of the top leading 
causes of mortality with one in nine deaths directly attributed to heart failure (Go et al., 
2014). As heart failure is a progressive terminal condition, it is imperative that the health 
care team discuss palliative care with this population during the course of their illness.  
The Institute of Medicine defines palliative care as “providing relief from pain 
and other symptoms, supporting quality of life, and focused on patients with serious 
advanced illnesses and their families” (Institute of Medicine, 2014, p 2-12). Presently, 
there are no known models to predict heart failure mortality specific to the skilled nursing 
facility (SNF) setting. Therefore, the ability to promote palliative care in this setting is 
limited. Having a viable SNF predictive mortality risk model could foster that discussion 
and prompt the planning for improved quality of care at the end stages of life.   
 Heart failure (HF) is defined as a “complex clinical syndrome that results from 
any structural or functional impairment of ventricular filling or ejection of blood” (Yancy 
et al., 2013). The term heart failure presently is the preferred medical description for this 
syndrome over the more commonly used term congestive heart failure. As no single test 
can determine this diagnosis, it is a syndrome diagnosed from data obtained from a health 
2 
 
history, physical examination, and clinical testing. Classically, HF manifests with 
symptoms of dyspnea and fatigue (Yancy et al., 2013). 
 The syndrome of HF bifurcates into two main diagnostic components: a) patients 
with reduced ejection fraction (HFrEF) labelled systolic heart failure, and b) patients with 
preserved ejection fraction (HFpEF) labelled diastolic heart failure. Ejection fraction (EF) 
is the measure of blood ejected from the left ventricle with each heartbeat into the aorta to 
feed the circulatory system. The American Heart Association (AHA) defines 50-70% EF 
as normal range ejection volume (AHA, 2016). 
 Heart failure is preceded by many health conditions that cause the myocardium to 
stretch and thicken (hypertrophy). This reduced pumping capacity is evident in HFrEF 
with <40%EF which comprises about 50% of cases of heart failure (Owan et al., 2006). 
Borderline HF patients have EF’s between 40 and 50% and may have no symptomology. 
Left-sided HF is more common than right-sided failure and is usually present prior to 
both ventricles being affected (AHA, 2016). 
Heart Failure Mortality 
 
 The lifetime risk for developing the syndrome is 20%, making HF a priority of the 
Centers for Medicare and Medicaid Services (CMS), the primary payer of care for this 
population (Djousse et al., 2009). By the year 2050, one in five Americans over 65 years 
old will have HF (Yancy et al., 2013). Incidence for those between the ages of 65 to 69 is 
20 cases per 1000 individuals compared to greater than 80 cases per 1000 for individuals 
greater than 85 years old (Curtis et al., 2008). From the Medicare population database (65 
years old and greater and those on Social Security disability), the incidence of HF has 
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increased from 90 to 121 cases per 1000 individuals for the ten years preceding 2003 
(Curtis et al., 2008).  
Survival after diagnosis of HF has improved due to enhanced clinical 
interventions and medical technology. Absolute survival from time of diagnosis remains 
steady with approximately 50% dying within 5 years (Alter et al., 2012; Yancy et al., 
2013). Those less than 50 years old had a longer life span (18.17 years +/- 6.99 years) 
compared to the octogenarian males that lived an average of 2.9 years (Atler et al, 2012). 
Pressler (2011) cited data from Get-With-The Guidelines – HF (an American Heart 
Association initiative) noting one-year post hospitalization skilled nursing facility (SNF) 
mortality was 53.5% compared to 29% for home bound discharges, reflecting greater 
frailty in the SNF care setting.   
 Heart failure is the primary Medicare hospital diagnosis in the United States 
representing greater than 1 million admissions annually (Allen et al., 2011; Yancy et al., 
2013). Patients admitted with HF have a 30-day readmission rate of 25% for all cause re-
hospitalization despite significant interventions to minimize that recidivism (Eapen et al., 
2013; Feltner et al., 2014; Yancy et al., 2013). Furthermore, nearly 10% of the HF 
patients admitted to the hospital died within 30 days of admission (Eapen et al., 2013). 
Repeat hospitalization is common with 83% hospitalized at least once per year and 43% 
at least 4 times per year (Yancy et al., 2013) making heart failure one of the costliest 
diagnoses to the Medicare program. Charges to Medicare and Medicaid programs 
account for about $30 billion annually (Yancy et al., 2013). The yearly mean cost/patient 
of hospitalization is $23,077 and can be higher when HF is the secondary diagnosis. 
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Palliative care has been shown to reduce hospitalization and improve the health-related 
quality of life for heart failure patients (Zuckerman et al., 2016).  
Zuckerman et al. (2016) identified that hospitalization length of stay for hospice 
patients was less (generally 1-5 days overall) and spending was $900-$5000 less when 
hospice was utilized. Medicare funded hospice is an approach to providing palliative care 
to those who have a terminal condition and a life expectancy of less than six months 
(CMS, 2016). It is reimbursed by Medicare and in some states, by Medicaid. Hospice 
care can be provided in SNFs, in a patient’s home, or in a designated hospice facility.  
Palliative care is the holistic integration of symptom management that includes 
discussion and planning with the patient and their family. It may include curative care 
that can benefit the patient and family if expected to improve their quality of life (Hupcey 
et al., 2009). Thus, having a heart failure predictive mortality model available for HF 
patients in SNF’s has the potential to improve the quality of life for the frailest of the 
frail. 
Because HF is a terminal condition, patient discussions about end of life 
preferences with their providers should occur early upon establishing a HF diagnosis 
(Hupcey et al., 2009; Whellan et al., 2014). Palliative care discussions should focus on 
the options and benefits of palliative care with the intent of identifying patient and 
family’s preferences to achieve the optimal quality of life for their remaining lifespan 
(IOM, 2014). Hupcey et al. (2009) identified in their systematic review of literature that 
patients with this diagnosis are not receiving palliative care, even at the end of life.  
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The Skilled Nursing Facility Heart Failure Patient 
 
CMS defines skilled nursing facilities (SNFs) as centers that furnish short-term 
nursing and rehabilitation and long-term residential nursing care to their beneficiaries 
(CMS, 2016). These facilities provide care to those who are not able to be cared for at 
home or in another community-based setting. Medicare services in SNFs generally 
include skilled nursing care, medical care, and related services including rehabilitation 
for admissions caused by injury, disability, or illness. Medicaid services are identical to 
Medicare except rehabilitation is not generally provided. Care for all SNF patients is 
based upon a regulatory mandated Resident Assessment Instrument-Minimum Data Set 
3.0 (RAI-MDS 3.0).  
 Today, there are 15,655 SNFs in the country providing care funded by Medicare, 
Medicaid, managed care, private insurers, Accountable Care Organization (ACO) 
networks, and private funding sources (American Health Care Association, 2020). 
Approximately 2.3 million patients were cared for in this setting in 2014 (Medpac, 2016). 
In fiscal year 2014, CMS provided coverage to 1.7 million fee for service (FFS) 
beneficiaries in SNFs with total costs at $28.6 billion (Medpac, 2016). These patients 
have multiple comorbidities and generate substantial costs to the Medicare program. 
These beneficiaries are older, frailer, predominantly female, disabled, and often dually 
eligible for Medicare and Medicaid payment (Medpac, 2016). 
Approximately 24% of hospitalized HF patients are discharged to a SNF (Jung et 
al., 2012; Jurgens et al., 2015). The remaining 22.3% are referred to home health care and 
53.6% to self-care at home (Allen et al., 2011). HF diagnosis is highly prevalent in SNFs 
with estimates of between 20% and 37.5% (Jurgens et al., 2015). For those admitted to a 
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SNF, repeat hospitalization is common with 83% re-hospitalized at least once per year 
and 43% at least four times each year (Heidenreich et al., 2011). 
Palliative Care in the Skilled Nursing Facility  
 
 HF patients in SNFs have a 76% greater risk of 5 year mortality compared to 
those discharged home due to the presence of multiple comorbidities and their frailty 
(Allen et al., 2011). Jurgens et al. (2015) identified that 53.3% of SNF patients with heart 
failure die within one year of admission. Therefore, advance directives and palliative care 
planning for this population is essential for proving quality end of life care (Leclerc et al., 
2014). Despite significant advances in the development of mortality prediction models 
for HF, little progress has been made in implementing these models in SNFs (Jurgens et 
al., 2015). While the Palliative Performance Scale is widely used in the hospice setting, 
the data directly obtained from the SNF assessment instrument does not correlate with 
this scale.  
It is essential that clinicians discuss with patients and their families palliative care 
versus curative interventions in the SNF setting to improve understanding of patient and 
family’s wishes for quality at the end of life (Allen et al., 2011). Hospitalizations 
decrease as the needs and wishes of the HF patient are honored through palliative versus 
curative interventions. Butler et al. (2015) found that less than 20% of hospitalized heart 
failure patients have an advance directive (an indication of planning for end of life). Of 
these, less than 2.5% of HF patients are discharged to hospice for palliative care, a clear 
indication of the need for discussion regarding palliative and end of life care with this 
terminally ill population (Butler et al., 2015). Providing hospice and palliative care 
interventions improves quality of life through symptom and pain management using a 
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holistic multidisciplinary approach. This approach is best used throughout the course of 
caring for patients with any terminal illness (Whellan et al., 2012).  
Heart Failure Mortality Risk Models  
 
 Despite significant advances in the treatment of HF in recent years, it is still 
uncommon for practitioners in any health care setting to discuss eventual mortality or 
palliative care with this population (Hupcey et al., 2009). Heart failure survival and 
mortality risk is widely discussed in current literature. However, existing mortality risk 
instruments/models are not easily implemented in the SNF setting due to limited 
availability of clinical data required in these models. In fact, most risk instruments are not 
easily implemented in the hospital setting for the same reason (Rahimi et al., 2014). The 
development of a SNF HF mortality risk model using data available in the SNF would 
facilitate palliative care planning with this population.   
The SNF Minimum Data Set Assessment Instrument (RAI-MDS 3.0)  
 
In 1990, CMS developed a universal assessment instrument titled the Resident 
Assessment Instrument-Minimum Data Set Centers for Medicare and Medicaid Services 
(2008). The intent was to standardize the data collected upon admission and throughout 
the patient’s stay in the SNF. This assessment instrument has been regularly updated and 
is currently in version 3.0. The RAI-MDS 3.0 must be completed by day five after 
admission, day 14, day 30, and then quarterly with an annual comprehensive assessment 
update. These assessment dates vary for type of admission but generally follow the 
preceding sequence. If the patient has a significant change in condition, as defined by the 
CMS RAI-MDS user’s manual, the assessment is updated and submitted to CMS for 
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notification of status change. The RAI-MDS 3.0 is completed on all patients regardless of 
payment source. It is also completed at time of death or discharge reflecting the end of 
the assessment cycle. This lengthy 40-page standardized assessment instrument provides 
a rich database to potentially identify mortality risk for HF patients in SNFs. Pocock et al. 
(2013) identified that many factors are present on this instrument that may be useful in 
mortality prognostication in this setting.  
Purpose and Aims of this Study 
 
 The purpose of this study was to determine the predictive risk of mortality 
associated with variables linked to heart failure that are routinely assessed using the RAI-
MDS. Knowledge of the mortality risk for patients with heart failure could be used to 
develop a model that improves care and quality of life for terminally-ill heart failure 
patients residing in SNFs.  
 In the literature, there are at least 117 HF mortality risk models and 249 predictive 
variables (Ouwerkerk et al., 2014; Rahimi et al., 2014). Presently, there are no known 
valid and reliable HF mortality risk instruments relevant to the SNF using data in the 
RAI-MDS 3.0 assessment tool. Creating a predictive model utilizing existing assessment 
data would facilitate adoption of palliative care practices in SNFs for the patient whose 
life expectancy is severely limited. Therefore, the specific aim of this study was: To 
determine which RAI-MDS 3.0 variables statistically predict heart failure mortality based 
on the domains of demographics, symptomology, diagnoses, and hospitalizations.  
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Significance to Nursing 
 
 The nursing profession, as defined by the American Nurses Association, is 
dedicated to “the protection, promotion, and optimization of health and abilities, 
prevention of illness and injury, facilitation of healing, alleviation of suffering through 
the diagnosis and treatment of human response, and advocacy in the care of individuals, 
families, groups, communities, and populations” (American Nurses Association, 2015). 
Registered nurses (RNs) identify and plan the care of patients in the SNF setting as 
required by CMS regulations (CMS, 2016). This is accomplished through 
interdisciplinary collaboration with the attending physician and other disciplines involved 
in the patient’s care. The Omnibus Budget Reconciliation (OBRA) Act of 1987 
specifically states that each resident (patient) must “achieve the highest practicable 
physical, mental, and psychosocial well-being” (OBRA,1987). Interpretation of this 
statutory requirement implies that care must be provided to meet the resident/patient’s 
needs and provide for optimum quality of life (OBRA, 1987). 
Presently, CMS, the federal regulatory agency, has not specified palliative care 
assessment nor created a model using the RAI-MDS 3.0 assessment to prompt palliative 
care discussion. A mortality risk tool that identifies those HF patients who are nearing 
their end of life would provide a structured mechanism to implement palliative care 
interventions and improve patient quality of life.  
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Significance to Patients and Their Families 
 
Implementation of a heart failure mortality risk tool has tremendous potential to 
positively affect the quality of life for the terminally ill HF patient and their family. Such 
a tool would facilitate engagement of the patient and their family in making personalized 
choices about their care and future. This has been emphasized in the 2016 CMS skilled 
nursing facility regulations requiring resident/patient centered care planning (CMS, 
2016). Creation of a mortality risk model using identified RAI-MDS 3.0 factors would  
facilitate holistic systematic palliative care planning by nurses in the SNF care setting and 
provide opportunities to improve patient and family quality of life and care.  
Summary 
 
The prevalence of heart failure in the United States is significant and growing 
(Vigen et al., 2013). In the SNF care setting, HF accounts for approximately 25% or more 
of the patient population. HF is a terminal condition and patients can benefit from 
palliative care to improve quality of life at end of life. Limited tools or systematic 
approaches are available in the SNF care setting to guide nurses in identifying those HF 
patients nearing end of life. Creation of a heart failure mortality predictive risk model 
based on data from the RAI-MDS 3.0 assessment instrument is a viable approach to 
identifying terminally ill patients and improving quality care at end of life.  
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CHAPTER II: REVIEW OF THE LITERATURE 
 
Philosophical Underpinnings and Conceptual Framework 
 
The purpose of this research study was to identify variables in the RAI-MDS 
assessment tool that could be used to develop a mortality risk model for HF patients 
residing in SNFs. Such a model could ultimately be used to improve the patient’s quality 
of life. The purpose of conducting nursing research is to generate, test, and find 
applications of theoretical or conceptual approaches that will produce a benefit for the 
overall population (Fawcett, 1999). It is a systematic process that is formal, rigorous, and 
tests concepts and propositions with the goal of contributing to new nursing knowledge. 
From an epistemological perspective, the positivist approach is warranted in this 
study as the researcher is seeking new knowledge pertaining to quantitative data 
contained within the RAI-MDS 3.0 instrument. Positivism uses observable data, and 
therefore, its end product can be generalized (Remenyi et al., 1998), which is the desired 
outcome of this study. Positivism uses objective reality and attempts to hold the 
researcher’s personal biases in check in the process of evaluating the phenomena (Polit & 
Beck, 2008). This approach allows the researcher to test the phenomena that is being 
studied to discover relationships about the studied data (Polit & Beck, 2008). One key 
component of positivism is the value-free nature in the way the research is undertaken. 
As this study utilizes tangible data from an existing instrument that is valid and reliable, 
and these data were collected by registered nurses not associated with the researcher, the 
potential for biasing the data is limited.   
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The Conceptual Model  
 
This research study aimed to analyze the RAI-MDS 3.0 patient data and identify 
variables that predict heart failure mortality in a subgroup of skilled nursing facility 
patients. This study is framed in a conceptual model that drives quality improvement of 
care and services. “A conceptual model is a set of abstract and general components and 
propositions that integrate into a meaningful configuration: synonymous with conceptual 
framework, conceptual system, paradigm, and disciplinary matrix (Fawcett, 1997, p13-
14)”. The conceptual framework for this study is Donabedian’s Quality of Medical Care 
Model, which provides a framework to examine health care services and the quality of 
care that those services provide. Donabedian (2005) developed this model for evaluating 
and improving the quality of health care including systems of care delivery.  
The Donabedian Quality of Medical Care model includes three components. The 
first component is described as structure or the setting in which care is provided that 
includes such elements as adequacy of the facility, staffing, qualifications of staff, and 
equipment. The second component that is necessary in this approach is processes of care, 
which are the mechanisms by which care is delivered to the patient. These processes 
include how care is systematically provided, what is done by each care participant, and 
the underlying supportive process to assure consistency. Care providers rely on the 
organization’s structural and systems framework to produce the desired quality result. 
The last component of Donabedian’s model is outcomes, defined as the relevant measure 
of the success of the systematic approach and identifies the expected result (Donabedian, 
2005).  
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The Agency for Healthcare Research and Quality publication “Closing the 
Quality Gap: A Critical Analysis of Quality Improvement Systems” (McDonald et al., 
2007) exemplifies the application of the Donabedian model. It demonstrates that the 
underlying framework of a quality improvement focus is on systems of care to drive 
quality outcomes. The agency’s approach applying the Donabedian model is further 
supported by the Andersen Behavior Framework (McDonald et al., 2007). This study 
utilizes a combined approach at the system level of quality improvement within an 
organization and the desired behavior of nurses in applying the risk model with their 
patients.  
Utilizing Donabedian’s conceptual model, structure in this research study is 
exemplified by the clinical setting in which care is provided; the SNF facility. This 
includes the physical environment, the staff involved in delivering care, and the patients 
who receive that care. The process in this study is the analysis of key health status 
indicators provided in the RAI-MDS 3.0 assessment instrument that are utilized across all 
SNF settings. This is the extracting of identified RAI-MDS 3.0 variables within the 
context of a HF mortality risk model. The outcome in this study was directed towards 
improved quality of life at end of life for heart failure patients by having a HF risk 
mortality model. Figure 1 reflects the conceptual empirical structure of this research 
study within the framework of Donabedian’s model of quality of medical care 
(Donabedian, 2005).  
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Figure 1 
 
Philosophical Framework 
 
 Moorhouse, Mallery, and Kolcaba are clinical theorists who frame the logic in 
this research study and support the need to develop a heart failure mortality risk model. 
Each of their philosophies embody the perspective that care should be rendered to 
patients within the framework of comfort and harmonization of their wishes.   
Moorhouse and Mallery (2012) developed a model entitled “Palliative and 
Therapeutic Harmonization (PATH)”. PATH was developed based on initially evaluating 
frailty among the elderly. This model takes into account patient and family preferences 
for ethical consideration evaluating whether care at end of life should indiscriminately 
provide aggressive curative treatment or foster discussion around palliative care in the 
decision-making process (Mallery and Moorhouse, 2011). Moorhouse and Mallery 
(2011) consider the ethical responsibility of respecting that patients want and deserve 
valid, honest, and forthright information about their prognosis. These authors purport that 
Figure	1.
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the best health care decisions are made when full consideration is given to the risks and 
benefits of treatment and the empowerment of patients and families in the decision-
making process.      
Moorhouse and Mallery (2012) refined their ethical model and developed a 
PATH model for long term care with the intent of improving quality of geriatric care. 
They recognized that frailty was a key predictor in the elderly that created additional 
vulnerability for the patient and family. The model notes that frail elderly are faced with 
multiple comorbidities, subject to poor outcomes, and unfavorable responses to 
traditional medical treatment. The researchers identified that: (a) there was a lack of a 
systematic approach in addressing the patient’s care needs in the context of comorbid 
conditions, (b) they needed to find a way to communicate sound information to the 
patient and family, and c) to empower these patients and families to determine their care 
and fate (Moorhouse and Mallery, 2012). 
The PATH model determines frailty utilizing the Clinical Measure of Fitness and 
Frailty Scale (Rockwood et al., 2005). This is in combination with a comprehensive 
geriatric assessment, the first step in the process is gaining an understanding of the 
patient’s health status and disease trajectory. This assessment includes  major 
comorbidities, functional status, social isolation or inclusion, mobility, cognitive status, 
and their degree of frailty. With this comprehensive understanding of the patient’s status, 
the next step in the PATH model is to communicate pertinent information in a semi-
structured manner to ensure that the patient and family have a comprehensive 
understanding of their status and options (Moorhouse and Mallery, 2012). 
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The last step in the PATH model is the empowerment stage. Clinical practitioners 
discuss the foreseeable future with the patient and family and encourage their 
empowerment to make health care decisions for their future. The key component of these 
three steps in the model is communication with the patient and family about their 
decisions at each encounter and transferring that information to all care providers. This 
last component is essential in the ability of the health care team to develop and 
implement a care plan that is reflective of the wishes of each patient and their family 
(Moorhouse and Mallery, 2012). This model is aligned with the goals of this study in 
empowering the nurse and health care team to have open and honest discussions about a 
patient’s future. 
Moorhouse and Mallery (2012) describe current end of life for frail adults as: (a) 
complex with comorbidities that are not always treated with evidence based medicine, 
sometimes leading to avoidance of the discussion of prognosis, (b) having limited 
awareness of the patient’s frailty, (c) having a lack of attention to the terminal condition, 
(d) the potential and usual withholding of comfort measures including pain management, 
(e) futile treatment being continued, and, (f) insensitivity to the needs of the patient and 
family.  
The PATH model is a theoretical and practical framework for holistically 
addressing patient frailty and the appropriateness of a care plan for each patient based 
upon comprehensive assessment, effective and realistic communication, and lastly, 
patient empowerment to make sound decisions that are right for each patient. This 
provides a standardized approach to include the heart failure patient and family in the 
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decision-making process at end of life applied in this study model within the conceptual 
framework of Donabedian’s model for quality of care.  
Katherine Kolcaba, a middle range nursing theorist, espoused a vision for holistic 
health care addressing comfort. Kolcaba (2003) describes her Theory of Comfort as 
patient centered, important to the patient and their health, and lastly, important to the 
viability of the care institutions where comfort should be a major driver in care delivery. 
From an ethical perspective, comfort care provides beneficence for the patient and allows 
nurses’ autonomy in addressing each patient’s needs. Her theoretical model also frames 
this study as the purpose of palliative care is to provide comfort and quality of life to the 
dying patient. The foregoing theorists provided great insight and guidance to this study 
and frame the rationale for the study.  
Literature Review 
 
 As there is a plethora of literature on models to predict either HF 
survival or mortality risk, the literature review focused on the most relevant research 
studies applying mortality risk models to heart failure patients. However, none of the 
literature reviewed identified a model that could be readily utilized in the SNF setting. 
The searchfor this study was initiated beginning with the year 2000 until present to 
identify current HF mortality prediction models. The following key words were used to 
search for articles in CINAHL and PubMed databases: end stage heart failure, mortality 
risk, heart failure models, and palliative care. Key words were truncated where 
appropriate to explore all related possible articles. Abstracts of articles were reviewed for 
relevance and appropriate articles were obtained for review.    
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Review of key clinical practice guidelines from the American College of 
Cardiology Foundation in partnership with the American Heart Association (Yancy et al., 
2013) were also included as these are updated every five years and provide evidence-
based practice guidelines (AHA/ACCF, 2013) for the care of the heart failure population 
across all disciplines. Additional references from these guidelines were reviewed so as to 
provide pertinent concepts, facts, and additional relevant evidence. 
Heart Failure Risk Factors Identified 
 
The overarching purpose of this literature review was to identify HF mortality risk 
models and their predictive factors within the domains of demographic characteristics, 
symptomology, and comorbidities. Heart failure is a syndrome of many different and yet 
related risk factors and diagnoses that affect the optimum functionality of the heart and 
survival of the patient. As heart failure develops and evolves over time, it is essential to 
evaluate the etiology of this syndrome from disease precursors and other known 
comorbid diagnoses identified in the AHA/ACCF (Yancy et al., 2013) guideline and 
related literature. 
Hypertension 
 
Elevation of both systolic and diastolic blood pressure (BP), particularly untreated 
hypertension, are major etiologic risk factors for the development of HF (Yancy et al., 
2013). While 82% of patients with hypertension are aware of the risks that their diagnosis 
has on mortality, only 75% are using prescribed antihypertensive agents, and 25% are not 
being treated for this diagnosis known to lead to HF. Only 53% of these patients 
diagnosed with hypertension are considered to be controlled to target normotensive 
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guidelines (Baker, 2002) which reduces their risk of HF. Effective BP treatment can 
influence and significantly reduce the potential to develop HF by about 50% (Baker, 
2002). Those diagnosed with hypertension have a significantly greater chance of 
developing HF than those with normotensive blood pressure (Baker, 2002).  
Diabetes Mellitus 
 
 Diabetes mellitus (DM), an etiologic risk factor causing microvascular damage, 
greatly impacts the progression of HF and the mortality of those diagnosed with the HF 
syndrome (Shindler et al., 1996). DM increases the propensity of developing HF even for 
those patients who do not have previous cardiac issues (Krumholz et al., 2000). 
Clinically, the heart of a patient with diabetes will show cardiac hypertrophy, dilation, 
and depressed vascular performance, all evidence of heart failure. These changes are 
accelerated in the presence of hypertension (Frustaci et al., 2000; Nasir & Aguilar, 2012). 
Obesity 
 
Obesity is also a significant etiological risk factor for HF. Increased body mass is 
associated with increased risk of heart failure (Kenchaiah et al., 2002). Compared to 
those with ideal body mass, those who were obese had double the potential for heart 
failure. In the United States, 154.7 million adults are overweight or obese representing 
68.2% of the population with 35% being defined as obese (Go el al., 2014).  
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Atherosclerotic Heart Disease 
 
The last major etiologic risk factor identified by the 2013 American College of 
Cardiology Foundation/ American Heart Association clinical guideline for the 
management of heart failure is atherosclerotic heart disease. Patients with atherosclerotic 
disease are more likely to develop HF (Yancy et al., 2013). 
Other Etiological Risk Factors 
 
Other HF risk factors identified in the AHA/ACCF guidelines that may or may 
not be listed on the RAI-MDS 3.0 are noted here and will not be expanded upon in this 
manuscript. Etiology of heart failure includes: (a) dilated cardiomyopathy, (b) familial 
cardiomyopathy, (c) endocrine and metabolic cardiomyopathy, (d) diabetic 
cardiomyopathy, (e) thyroid disease, (f) acromegaly, (g) toxic cardiomyopathy, (h) 
cocaine cardiomyopathy, (i) cardiotoxicity related to cancer treatments, (j) myocarditis, 
(k) AIDS, (l) Chagas disease, (m) hypersensitivity myocarditis, (n) rheumatological and 
connective tissue disorders, (o) amyloidosis, (p) cardiac sarcoidosis, and (q) Takotsubo, 
or stress related cardiomyopathy (Yancy et al., 2013). 
Frailty  
 
Frailty is defined as the compromised ability to cope with physiological stress and 
is common in the SNF patient (Jurgens et al., 2015). While comorbidity is not the same 
as frailty, two or more comorbid conditions creates a risk factor for frailty (Jurgens et al., 
2015). One of those indicators of frailty for the HF patient is determined by using the 
New York Heart Association (NYHA, 2017) classification system. Heart failure 
functional capacity classification is based upon the New York Heart Association 
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functional limitation model (NYHA, 2017). This classification system evaluates 
functional capacity relative to symptom severity. Class one (I) indicates minimal to 
moderate limitation of functional capacity and activities, with class four (IV) indicating 
very limited exertion causing functional impairment and limited quality of life. Those HF 
patients classified as NYHA III –IV are impacted the most and those at class IV have 
limited ADL function and have poor health-related quality of life. 
Comorbid Diagnoses 
  
Murad et al. (2015) evaluated the burden of comorbidities relative to functional 
and cognitive impairment in patients initially diagnosed with heart failure and assessed 
the impact of these on mortality. Using data from the Cardiovascular Health Study 
(CHS), a population based longitudinal study evaluating various factors in adults over 65 
years old with cardiovascular disease funded by the National Institute of Health, the 
authors examined the prevalence of nine comorbidities and four functional and cognitive 
impairments in 5888 subjects who developed HF between 1990 and 2002. The HF 
sample was extracted from 5,888 study participants (patients) from four counties. The 
participants were evaluated prospectively until mid-2008. The mean age at the time of HF 
diagnosis was 79.2 +/- 6.3 years and approximately half were male. Sixty percent of these 
patients had three or more comorbidities and only 2.5% had none. Seventeen percent had 
cognitive impairment. The mortality rate for the 504 subjects who died within one, four, 
and ten years were respectively 19%, 56%, and 83%. The median survival was 4.3 years. 
Using a multivariate adjusted model, the following diagnoses had the greatest mortality 
risk: (a) diabetes [HR 1.64, 95% CI: 1.33- 2.03], (b) chronic kidney disease [HR 1.32, 
95% CI:1.07-1.62], (c) moderate kidney disease [HR 3.00, 95% CI:1.82-4.95], (d) 
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cardiovascular disease [ HR1.53, 95% CI: 1.22-1.92], (e) depression [ HR 1.44, 95% 
CI:1.09-1.90], (f) functional impairment of 1 IADL [ HR1.30, 95% CI; 1.04-1.63], (g) 2 
or more IADL impairments [HR 1.49, 95% CI:1.07-2.04], and (h) cognitive impairment 
[HR1.33, 95% CI: 1.02-1.73]. Other comorbidities not associated with mortality in this 
study were hypertension, coronary artery disease, peripheral arterial disease, atrial 
fibrillation, obstructive pulmonary disease, and functional impairments. The authors 
concluded that elderly HF patients often have a high burden of comorbidities with 
functional and cognitive impairments that are associated with greater mortality risk.    
Saczynski et al. (2013) studied the effects of comorbidities on mortality in 23,435 
individuals diagnosed with heart failure using data from the National Heart, Lung, and 
Blood Institute sponsored Cardiovascular Research Network PRESERVE study, a large 
multicenter community-based study. The authors compared predictors and outcomes in 
both HFpEF and HFrEF patients. The Charlson/Deyo Comorbidity Index, which weights 
the sum of medical conditions (higher scores indicate more comorbidity), was used.   
In this study, 53% of the sample had preserved EF, of which, 60% were female. 
Three quarters of the sample had three or more comorbid conditions and half had five or 
more. Common comorbidities included hypertension and dyslipidemia occurring in more 
than a quarter of the sample. Those with HFpEF had a slightly higher comorbid status of 
4.5 versus 4.4 for HPrEF (P=.002). The authors determined that there was a high degree 
of comorbidity in both the HFpEF and HFrEF subgroups. The burden and pattern of 
comorbidity varied only slightly between the two groups. 
 
 
23 
 
Advanced Heart Failure 
 
The European Society of Cardiology (Metra et al., 2007) definition of advanced 
HF is severe functional impairment (NYHA III-IV). Risk factors for advanced heart 
failure include: (a) dyspnea and/or fatigue at rest or with minimal exertion, (b) episodes 
of fluid retention, (c) objective evidence of severe cardiac dysfunction by at least one of 
the following (LVEF < 30%, mitral inflow pattern disruption, pulmonary capillary wedge 
pressure of  > 16 Hg  or RAP of  > 12mm Hg by pulmonary artery catheterization, or 
high BNP plasma levels in the absence of non-cardiac causes, (d) severe impairment of 
functional capacity, (e) history of hospitalization in the past 6 months, and (f), the 
presence of all of the previous features in spite of attempts to optimize therapy and care 
(Metra et al., 2007).    
Other clinical events that predispose a patient to being in the advanced stages of 
HF are: (a) greater than 2 hospitalizations or emergency department visits for HF 
symptoms in the past year, (b) progressive deterioration of renal function, (c) weight loss 
without other occurring causes, (d) intolerance to ACE inhibitors, (e) intolerance to beta 
blockers, (f) frequent systolic blood pressure of < 90 mm Hg, (g) persistent dyspnea with 
dressing or bathing needing rest, (h) inability to walk one block due to dyspnea, (i) recent 
need to escalate diuretics, (j) progressive decline in serum sodium, and, (k) frequent ICD 
shocks when devices were present (Yancy et al., 2013). These patients are terminal and 
are likely to die of sudden death and have extremely limited quality of life. 
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Mortality and Hospitalization 
 
Foebel et al. (2013) studied mortality and hospitalization in the SNF population 
using data from the GOLD-HF (Geriatric Outcomes and Longitudinal Decline in Heart 
Failure) Study. They followed 546 patients admitted to SNFs for up to one year. Using 
multivariate regression modeling and Cox proportional hazards regression, they 
determined the time to mortality predictors. Mortality overall was 42% for HF patients 
and 31% were hospitalized within that year. Interestingly, the major predictor of greater 
mortality was use of tranquilizers. Peripheral vascular disease was the strongest predictor 
of hospitalization. While this study was performed using data from SNFs, it did not 
produce a HF mortality risk assessment tool that could easily be applied in SNF setting 
using existing clinical assessment data. 
Age 
 
 Pocock et al. (2013) conducted a meta-analysis that included data from 39,372 
subjects and found that one of the strongest predictors of mortality in HF patients is age. 
Jurgens et al. (2015) identified that as individuals age, the number of comorbid 
conditions increase, increasing the risk of mortality in those with heart failure. Rahimi et 
al. (2014) evaluated risk factors across 43 models predicting HF and identified that strong 
predictors of mortality included age and gender. Clearly, as individuals age, the risk of 
increased comorbidity, frailty, and other heart failure factors increases the likelihood of 
mortality in this population. 
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Gender 
 
Klempfner et al. (2014) evaluated the effect of gender related to HF. The study 
showed that women [HR 1.16, 95% CI: 0.96-1.41, P = 0.13] tended towards an increased 
risk for early mortality versus men [HR 1.25, 95% CI: 1.09-1.43, P = 0.001]. Conversely, 
Chyu el al. (2013) evaluated four specific variables in modeling heart failure risk in men 
and women. Their study revealed that women had better survival than men at the one-
year endpoint and had higher event free survival for all-cause mortality than men. As 
noted from the two preceding studies, it is equivocal whether gender is influential in 
predicting HF mortality.  
Risk Factor Conclusions 
 
In summary, variables described in aforementioned heart failure mortality risk 
models informed the variables selected for this study. Only those variables that are 
available on the RAI-MDS 3.0 instrument and those known to be predictive from the 
literature review were evaluated in this research study. While functional decline is 
utilized in some of the mortality risk models, all patients in this study had limited 
functionality, which required them to be placed in a SNF. Therefore, functional decline 
was not evaluated as part of this study since it is an underlying characteristic of the study 
population. 
Heart Failure Risk Models Compared and Contrasted 
 
Levy and Anand (2014) evaluated the value and benefits of heart failure mortality 
prediction models. Model validation is important both for discriminatory value and 
calibration with another cohort. This is significant in that factors such as ethnicity, 
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genetics, and lifestyle may limit the accuracy of risk scores across populations. For 
example, in the Framingham study, the risk score for Asian patients was raised/inflated 
due to cultural differences (Levy & Anand, 2014).  
Levy et al. (2006) developed the Seattle Heart Failure Model (SHFM), the most 
widely known HF prediction model. The multivariate model predicts 1, 2, and 3-year 
survival of heart failure patients. The SHFM used data from 1,125 patients from the 
Prospective Randomized Amlodipine Survival Evaluation (PRAISE study) that was 
analyzed using Cox multivariate statistical methodology. This model was then validated 
prospectively in a sample of 9,942 patients from five other randomized controlled studies 
that included 17,307-person years. The strength of this model is the ability to add or 
delete medications and devices to observe the treatment effect using a calculator that can 
be loaded for free onto any computer or tablet. While this model is considered excellent 
and one of the easiest to use, the variables included in this model are not easily obtained 
in the SNF setting, such as biomarkers or diagnostic tests, and are not “captured” on 
the  RAI-MDS 3.0 instrument. Capturing data from the RAI-MDS is part of the process 
whereby a date is selected and nurses finalize the assessment, thereby “capturing” or 
collecting a “snapshot” of assessment data that describes that patient at that one point in 
time.  Further, the intent of this proposed study was to determine relevant mortality risk 
variables contained in the RAI-MDS instrument that does not require additional data 
capture or model input when used in a future predictive model. 
Ouwerkerk et al. (2014) performed a systematic review of existing HF prediction 
models extracting the corresponding patient characteristics that have been used to predict 
HF mortality outcomes, or hospital readmission. Studies were included only if the results 
27 
 
reported C statistics or receiver operating curve values. In their analysis, they identified 
117 HF mortality risk models in 55 papers reviewed. The models had a total of 249 
different variables. The best mortality predictors were a patient’s serum blood urea 
nitrogen level (BUN) and serum sodium level. Mortality predictability was enhanced 
when using many clinical variables. Their mean C statistic for mortality was 0.68 +/-
value of chronic versus the acute heart failure in these models.  
Pocock et al. (2013) conducted a meta-analysis using heart failure mortality risk 
studies with the aim of creating a generalizable mortality risk score for HF patients. The 
Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) data provided an 
opportunity for this research team to create an analysis that included data on 39,372 
patients having both HFrEF and HFpEF from 30 different cohort studies. Six clinical 
trials comprised 75.8% of the sample and included the DIAMOND (Distensibility 
Improvement and Remodeling in Diastolic Heart Failure) study, DIG (Digitalis 
Investigation Group) study, CHARM (Candesartan in Heart Failure Assessment in 
Reduction) study, and ECHOS (Echocardiography and Heart Outcome Study) and In-
CHF and HOLA registries. Methods were deployed to adjusted to account for missing 
data. Pocock et al. (2013) found that 42% of the patients died within the median follow 
up of 2.5 years.  
In this meta-analysis, Pocock et al. (2013) performed a multivariate piecewise 
Poisson regression using time of death from any cause, and forward stepwise regression 
for variable selection using p < 0.01 to identify 13 highly significant independent 
predictors of mortality in this population. These include in order of predictive strength: 
(a) age, (b) lower EF, (c) NYHA class, (d) serum creatinine, (e) diabetes, (f) no 
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prescribed beta-blocker, (g) lower systolic blood pressure, (h) lower body mass, (i) time 
since diagnosis, ( j) current smoker, (k) COPD, (l) male gender, and, (m) no prescribed 
ACE-inhibitor or angiotensin-receptor blocker. While age was most predictive in HFpEF, 
systolic blood pressure was less predictive in HFrEF. The Poisson model predictor was 
converted into an easy to use integer risk score with zero being lowest possible risk and 
50 being the highest risk producing 3-year mortality rates of 10% bottom decile and 70% 
top decile. Risk was predicted using this tool for 1 and 3-year survival/mortality.  
Rahimi et al. (2014) performed a systematic literature review and analysis of risk 
prevention models for HF patients attempting to identify the most consistently reported 
variables across models. This study gathered articles from MEDLINE and EMBASE for 
the period between January 1995 and March of 2013, yielding 2,678 abstracts with 
additional hand searches identifying other relevant studies. Eligibility for inclusion 
required that the published report have at least one multivariate model that predicted 
either death, hospitalization, or both in HF patients. However, none of these studies were 
conducted in the SNF population. Sixty-four models with 50 modifications were obtained 
and ranked from 48 studies that met this criterion. Forty-three models predicted death, ten 
predicted hospitalization, and eleven predicted death or hospitalization. Rahimi et 
al.(2014) observed wide variation in the study methodologies and settings, population 
characteristics, sample sizes, and variables included in the studies. Variables included 
diagnoses, psychological factors, and biomarkers (some captured from medical records, 
and others from administrative databases). A few strong risk predictor variables emerged 
from comparative analysis of risk assessment tools. These include: (a) age, (b) renal 
function, (c) blood pressure, (d) blood sodium levels, (e) left ventricular ejection fraction, 
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(f) sex, (g) brain natriuretic peptide level (BNP), (h) NYHA classification, (i) diabetes, (j) 
weight or BMI, and, (k) exercise capacity. Rahimi  et al. (2014) concluded that 
development of automated systems to obtain risk variables and analyze them would help 
to facilitate user application and foster communication with patients and families 
regarding their risks.   
Using the Seattle Heart Failure Model (SHFM), Fink et al. (2012) prospectively 
evaluated the impact of fatigue and depressive symptoms, along with immune 
biomarkers, relative to prognosis. The study included 59 patients with HFrEF that were 
attending outpatient clinics in the Midwest under the care of a cardiologist. The data 
suggest that fatigue (measured on the NYHA classification) with a covariate of 
depressive symptoms was positively associated with the SHFM score. Further, fatigue 
and depressive symptoms were important covariates in predicting poorer prognosis in the 
HFrEF population.  
Chyu et al. (2013) developed a four-variable risk model to predict mortality for 
heart failure patients. A sample of 2,255 HF patients were stratified by sex into both 
derivation and validation cohorts. The initial analysis consisted of 39 variables that were 
mainly non-invasive scores. Cox regression methodology was utilized to determine key 
variables predictive of either death/urgent transplant/or left ventricular assist device 
(LVAD) augmentation. The survival rate for the overall sample was 83.5%, 69.9%, and 
58.4% for years 1, 3, and 5 respectively. Despite some differences in the baseline data, 
the four strongest predictors of mortality were: (a) B-type natriuretic peptide, (b) peak 
oxygen consumption during cardiopulmonary exercise testing, (c) NYHA class, and (d) 
the use of Angiotensin Converting Enzyme-Inhibitors (ACE-I) or Angiotensin Receptor 
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Blockers (ARBs). The four-variable model was then converted into a point-based risk 
score. The C index was 0.79 for the Heart Failure Survival Score compared to the Seattle 
Heart Failure Model (SHFM) C index of 0.76. Both these scores indicate a good model.  
Betihavas et al. (2015) evaluated absolute risk prediction to determine unplanned 
cardiovascular readmissions for adult HF patients. The study included 280 subjects in a 
prospective multiple center randomized controlled trial comparing home versus clinic-
based interventions. Cox proportional hazards statistical modeling was employed to 
account for the competing risk of death. Results indicated that 13% were readmitted to 
the hospital within 28 days and 53% within 18 months. It should be noted that this study 
included home based subjects who were not considered overtly frail or in need of SNF 
care. This particular model had a C statistic of 0.80 with the following results: (a) age 
[HR 1.07, 95% CI: 0.90-1.26] for each 10-year increase in age, (b) living alone [HR 1.09, 
95% CI: 0.74-1.59], (c) living a sedentary lifestyle [HR 1.44, 95% CI: 0.92-2.25], and (d) 
the presence of multiple (5 or more) comorbidities [HR 1.69, 95% CI: 0.38-7.58]. While 
this model identifies short term risk of hospitalization, it is useful in this study in 
understanding the pre-acute risk factors prior to a SNF admission. 
Kommuri et al. (2012) evaluated 2,221 HF patients admitted to 14 Michigan 
hospitals during 2002-2004. The researchers used the EFFECT (Enhanced Feedback For 
Effective Cardiac Treatment) model that stratifies patients into low, medium, and high 
risk of hospitalization. The study found that for otherwise low risk patients, a history of 
two or more HF hospitalizations within the last year significantly increased one-year 
mortality.   
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Zomer et al. (2013), analyzed the frequency of HF admission to acute care and the 
mortality risk after first admission. The study sample consisted of 10,808 adult HF 
patients with a median follow up period of 21 years. Incidence of first time HF 
hospitalization was 1.2 per 1000 patient-years. Patients admitted for HF had a five-fold 
higher mortality risk than those not admitted or maintained through closer clinical 
management. The hazard ratio was 5.3 [95% CI:4.2-6.9]. One and three-year mortality 
for those admitted was 24% and 35%, respectively. The conclusion of their research 
indicated that the mortality risk is greatly increased after a HF hospital admission 
signifying the need to manage the patient closer medically and utilize medical 
interventions for stability.  
Corrao et al. (2015) studied a cohort of 13,171 Italian patients aged 50 and older 
that survived their first hospitalization for HF. These researchers found that using a 30-
day post hospital period, 4.7% died 30 days post hospital discharge, and 4.3% were 
readmitted to the hospital. Additionaly, 22.6% died and 57.2% were readmitted to the 
hospital within one year for any cause. They concluded that both short and long-term risk 
of mortality was high for this population. 
Chaudhry et al. (2013) evaluated the risk factors for hospitalization in 758 
patients newly diagnosed with HF. The mean hospitalization rate was 7.9 per 10-person 
years [95%; CI: 7.4-8.4]. The independent risk factors were; (a) diabetes [HR:1.36, 95% 
CI: 1.13-1.64], (b) NYHA class III or IV [HR 1.32; 95% CI:1.11-1.57], (c) chronic 
kidney disease [HR 1.32, 95% CI:1.14-1.53], (d) slow gait [HR 1.28, 95% CI:1.06-1.55], 
(e) depressed EF [HR 1.25, 95% CI:1.04-1.51], (f) depression [HR 1.23, 95% CI:1.05-
1.45] and (g) muscle weakness [HR 1.19, 95% CI:1.00-1.42]. The authors concluded that 
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if these conditions were modifiable through treatment, they should be assessed and 
treated when appropriate.  
In a study of 3,830 HF patients from the CORONA (Controlled Rosuvastatin 
Multinational Trial in Heart Failure) study, Perez-Moreno et al. (2014) identified that 
greater fatigue correlated with worsened clinical outcomes. The key predictor variable 
was dyspnea which correlated with left ventricular ejection fraction (LVEF). Dyspnea 
symptom severity was associated with higher risk of cardiovascular death and/or 
hospitalization. After adjusting for other variables, such as LVEF, NYHA class, and B-
type natriuretic peptide level, fatigue was associated with higher risk of hospitalization, 
and dyspnea increased the risk of worsened clinical outcomes.  
As there are almost equal percentages of HFpEF and HFrEF patients, it is 
important to identify which type of HF was included in the study sample. Sherazi et al. 
(2015) followed 191 patients with HFpEF of >40% with a mean age of 70+/-14.6 years, 
for 4.0 +/- 2.8 years. The 5-year mortality was 59% for men and 57% for women. Using 
multivariate Cox regression analysis, predictors were: (a) BUN > 25 mg/dL (HR 1.77, p 
= 0.002), (b) absence of hypertension (HR 1.58, p = 0.032), (c) left ventricular end 
diastolic dimension (LVEDD) ≤ 4.1cm (HR 1.73, p = 0.011 and (d) LVEF ≤ 45% (HR 
1.69, p = 0.027). They concluded that patients hospitalized for HFpEF had a high risk of 
mortality. Absence of hypertension, elevated BUN, and lower LVEF increased the risk 
for short and long-term mortality. A lower LVEDD was an independent predictor of 
mortality for this population. 
Senni et al. (2013) identified that the existing risk models had multiple 
limitations. They developed a simple model using existing clinical information including 
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cardiac and comorbid conditions that predicted all cause 1-year mortality. This tool was 
titled the Cardiac and Comorbid Conditions HF (3C-HF) Score. The tool was developed 
with a derivation cohort of 2,016 subjects and a validation cohort of 4,258 subjects. The 
median age was 69, about one third were female, 20.6% had a normal EF, and 65% had 
at least one comorbidity. The study results after 5,861 person-years of follow-up had 
12.1% meet the end point of all cause death. The variables that best predicted one year 
all-cause mortality included in descending order: (a) NYHA class III-IV, (b) LVEF<20%, 
(c) no beta blocker medication, (d) no renin angiotensin system inhibitor, (e) severe valve 
disease, (f) atrial fibrillation, (g) diabetes with micro and macroangiopathy, (h) renal 
dysfunction, (i) anemia, (j) hypertension, and (k) older age. The C statistic was 0.87 for 
the derivation and 0.82 for the validation group. This research team believed that this tool 
would be simple and easy to implement to improve the prognostication of disease 
progression in daily practice. While that may be the case in physician offices or in acute 
care settings, many of the variables are not easily obtained in settings like SNFs that 
universally use the RAI-MDS 3.0 instrument.  
Eapen et al. (2013) sought to develop heart failure prediction models using data 
elements from an electronic health record database to assess risk of 30-day re-
hospitalization and mortality of older HF patients. Their study extracted data from a large 
Medicare claims database so as to create and validate heart failure risk prediction tools. 
The study evaluated Get With the Guidelines-Heart Failure (GWTG-HF) subjects using 
claims data from January 2005 to December 2009. Eapen et al. (2013) selected variables 
based upon availability within the electronic health record (EHR) and prognostic value in 
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prediction. The models were randomly selected and contained both HFrEF and HFpEF. 
Sample size was 33,349 patients in 160 hospitals.  
Mortality rate was 9.1% within 30 days of hospital admission, 22.8% were 
hospitalized again within thirty days of discharge, and 27.2% died or were hospitalized 
within 30 days combined. High risk patients had a significantly higher odds ratio (8.82) 
of death with a); rehospitalization [OR 1.99, 95% CI:1.86-2.13] and the combination of 
both being [OR 2.65, 95% CI: 2.44-2.89]. This mortality model had a C statistic of 0.75 
with the rehospitalization and death/rehospitalization a more modest discrimination of 
0.59 and 0.62. The study determined that having predictive models for risk stratification 
for 30-day rehospitalization outcomes for HF patients could provide a validated point of 
care tool for clinicians to foster better decision making for this population.  
In a study by Sartipi et al. (2014), the researchers validated the MAGGIC (Meta-
Analysis Global Group in Chronic Heart Failure) risk score that utilized thirteen routinely 
available patient characteristics. The MAGGIC variables included: (a) age, (b) gender, (c) 
BMI, (d), current smoker, (e) systolic blood pressure, (f) diabetes, (g) NYHA class, (h) 
ejection fraction, (i) COPD, (j) HF duration, (k) creatinine, (l) beta blocker use, and (m) 
ACE inhibitor or ARB. The sample included 51,043 patients from the Swedish Heart 
Failure Registry and calculated the MAGGIC score using three-year mortality as the 
outcome metric. The study group had a mean age of 75 with 40% being female and 56% 
having HFpEF. The NYHA classification of the group was 57% class I or II, 38% class 
III, and 5% class IV. They compared the actual three-year mortality to the predicted 
three-year mortality of the MAGGIC score. The overall outcome for actual mortality of 
the patient group was 39.4% versus the predicted mortality of 36.4%. The observed to 
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expected ratio was 1.08. The C index was good at 0.741. It appeared that the MAGGIC 
risk calculation performed well in predicting mortality in this population. Overall survival 
was 80% at year one, and 61% at year three and one predictive variable identified was 
rehospitalization.   
Giamouzis et al. (2011) performed a literature review of the rehospitalization of 
HF patients. The review focused on risk factors, knowledge gaps, and risk prediction 
tools. Factors identified in the literature that prompted re-hospitalization included 
sociodemographic indicators including advancing age, socioeconomic status, racial 
heritage, smoking, and alcohol use. Other factors were clinical laboratory testing results, 
comorbidity burden, cardiovascular status, other clinical conditions, and some quality of 
life factors. Some of the studies examined reported higher risk of hospitalization for 
reduced EF, increased heart rate, higher NYHA functional classification, and prior 
hospitalizations for HF. The comorbidity burden increased the HF admission rate with 
39% having five or more comorbidities and only 4% with just a diagnosis of HF 
(Giamouzis et al., 2011). 
Giamouzis et al. (2011) also identified that one half of hospitalized HF patients 
were readmitted within six months. Seventy percent of those readmitted to the hospital 
were due to worsening of the previously treated HF. Further, Jenks et al. (2009) identified 
through Medicare data that this diagnosis is the number one cause of hospital 
readmission. Giamouzis et al. (2011) identified that more needed to be done to 
understand high risk HF mortality and how to improve the quality of life of this frail 
population.   
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Identification of Study Variables 
 
Variables for this study were selected based upon the identified factors most 
predictive of HF mortality and decline found in the previously cited literature review and 
were found in the RAI-MDS 3.0 instrument dataset. Table 1 in Appendix A lists the key 
variables that are contained within the RAI-MDS 3.0 either directly or via proxy variable, 
which was identified. While the RAI-MDS 3.0 has 41 potential variables, this study 
tested the identified variables to evaluate whether a SNF heart failure mortality risk 
model can be created using data from RAI-MDS 3.0, a required assessment instrument 
for residents of SNFs. The following represents the variables that were examined 
followed by the references of the studies that support their inclusion as found in Table 1 
in the Appendix.  
1. Hospital admission.  Hospitalization and rehospitalization are variables that 
consistently appear in the literature on risk factors for mortality in the heart 
failure population (Betihavas et al. (2015); Eapen et al. (2013); Giamouzis et 
al. (2011); Heidenrich et al. (2011); Kommuri et al. (2015); Ouwerkirk et al. 
(2014), and Zomer et al. (2013),  Because this study utilized a statistical 
methodology that requires a defined starting point, it included data from 
patients initially admitted to the SNF following an acute episode requiring 
hospitalization. This was indicated by a completed full RAI-MDS 3.0 
assessment.  
2. Expiration.  The study attempted to define mortality prediction variables and 
expiration is the crucial dependent variable. Expiration may or may not have 
occurred in the SNF (potential hospital admission and subsequent expiration) 
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but is documented on the instrument to close out the RAI-MDS assessment 
series submitted to Medicare and Medicaid if occurring during the window of 
2013-14. The study also defined expiration as discharged to an acute hospital 
return anticipated but not re-admitted in 14 days.( Betavius et al, 2015; 
Chaudry et al., 2013; Chyu et al., 2013; Eapen et al., 2013; Fonorow et al., 
2005; Giamouzis et al., 2011; Levy et al, 2006; Murad et al., 2015; Pocock et 
al., 2012; Rahimi et al., 2014; Sartipi et al., 2014; Senni et al., 2013; Yancy et 
al., 2013; Zomer et al., 2013).  
3. Age. Age was included as published HF risk models indicate HF mortality 
increases as a person ages. In this study, because it is not known when a 
patient was initially diagnosed with HF, it was assumed that it was prior to the 
most recent hospitalization causing SNF admission (Betihavas et al., 2015; 
Levy & Anand, 2014; Pocock et al., 2013; and Rahimi et al., 2014).  
4. Gender. Risk models indicate gender may influence HF mortality time frames. 
(Chyu et al., 2013; Levy & Anand, 2014; Pocock et al., 2013; Rahimi et al., 
2014, and Sartipi et al., 2014).   
5. Hospitalization after SNF admission. This variable was captured by analyzing 
discharge and readmission to the SNF. The RAI-MDS data base does not 
contain information on prior hospital admissions before the SNF admission, 
but does include readmissions subsequent to initial SNF admission. (Betihavas 
et al., 2015; Eapen et al., 2013; Giamouzis et al., 2011; Heidenrich et al., 
2011; Kommuri et al., 2015; Owerkirk et al., 2014; Zomer et al., 2013, and 
Yancy et al., 2013).   
38 
 
6. Comorbidities. Total number of comorbid conditions were included. (Allen et 
al., 2015; Betihavas et al., 2015, and Murad et al., 2015). 
7. Diabetes Mellitus (DM). While diabetes is also counted in the total 
comorbidity calculation, evidence supported capturing and evaluating this 
variable independent of the other comorbidities (Chaudhry et al., 2013; Murad 
et al., 2015; Rahimi et al., 2014; Senni et al., 2013, and Sartipi et al., 2014). 
8. Hypertension. Hypertension is an etiologic factor for the development of heart 
failure and was evaluated independent of the comorbidities in total. (Chyu et 
al., 2013; Fonorow et al., 2005; Levy & Anand, 2014, and Senni et al., 2013). 
9. Renal function. While serum laboratory results are not captured on the RAI-
MDS, this variable is specifically noted on the RAI-MDS 3.0 instrument as 
renal insufficiency, renal failure, or End Stage Renal Disease (Chaudhry et al., 
2013; Murad et al., 2015; Rahimi et al., 2014; Senni et al., 2013, and Yancy et 
al., 2013). 
10. Dyspnea. Shortness of breath with exertion, when sitting, and when lying flat 
was used to define dyspnea in this study. Dyspnea is a classic symptom of this 
syndrome and is indicative of NYHA class III and IV. It is a predictive 
variable in multiple risk models (Chaudhry et al., 2013; Chyu et al., 2013; 
Murad et al., 2015; Pocock et al., 2013; Rahimi et al., 2014; Sartipi et al., 
2014, and Senni et al., 2013 
Study Assumptions 
 
To conduct a study that defines the variables for a heart failure mortality risk model, 
the author made assumptions that form its foundation. Therefore, this study assumed that: 
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1. The RAI-MDS 3.0 data were accurately obtained by nurses. 
2. The data obtained were accurately entered into the RAI-MDS 3.0 instrument. 
3. The existing heart failure mortality risk models are valid and reliable. 
4. The proxy variables adequately represent the mortality risk model variables. 
5. The obtained database reflects the heart failure population in SNFs across the 
United States.  
This research study is unique in that statistical evaluation of presumed predictive 
variables that can be used to create a mortality risk model for HF patients residing in 
SNFs has not previously been published in scientific literature or made available in the 
SNF health care setting. It was assumed that incorporating variables included in 
published valid and reliable HF mortality/survival risk models would ultimately lead to 
the development of a valid and reliable tool that can be used in the SNF setting to 
improve quality of end of life care for HF patients in this setting.  
Research Question and Aims 
 
The overarching aim of the study was to examine factors associated with heart 
failure and determine their respective risk for mortality for those who reside in SNFs. 
Based on this, the research question guiding this study was: Which factors associated 
with heart failure included in the RAI-MDS had the greatest risk to cause death in skilled 
nursing home patients? The elucidation of these predictive factors has the potential to 
enable the creation of a heart failure mortality risk model and future mortality risk tool 
for individuals with HF. Based on the review of the literature the following variables 
were explored:   
• hospital re-admission   
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• diagnosis of renal failure, renal insufficiency, or being on dialysis  
• diagnosis of hypertension  
• diagnosis of dyspnea  
• diagnosis of diabetes  
• age of 65 to 84 years old  
• age 85 years old and older  
• male gender  
• presence of three or more diagnoses  
Gaps in the Literature 
 
While there has been extensive research and publication of valid and reliable HF 
mortality risk tools, none have been created or published using data from the RAI-MDS 
3.0 instrument in the SNF setting. Each of the published risk models utilize different and 
unique variables, many of which are not captured in the SNF setting. If these variables 
are captured in the SNF, they are not consistently documented or transferred in the 
transition from acute care to post-acute care (SNF) and are not found on the RAI-MDS 
3.0 instrument.     
It is important to note that the SNF health care setting has extensive statutory and 
regulatory requirements of participation in the Medicare, Medicaid, and state licensure 
programs. These requirements create an extensive burden of documentation, systems 
design, and execution. In this practice setting, it would increase the nursing work burden 
if the mortality risk model is not derived from an existing patient assessment instrument. 
Requiring an additional assessment tool would most likely not be accepted or embraced 
in this setting.  
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CHAPTER 3: Research Design and Methods 
 
This study was a retrospective cross-sectional exploratory analysis of factors 
embedded in the RAI-MDS 3.0 instrument that predict mortality in patients with heart 
failure who reside in SNFs. The study sample was comprised of a cohort of patients with 
a primary or secondary diagnosis of heart failure who were admitted to SNFs which were 
part of a multi-facility organization in the Midwest during the years 2013-2014. Based on 
the review of published studies and heart failure mortality models, relevant variables 
associated with HF mortality were extracted from an existing RAI-MDS 3.0 database 
from 24 SNFs. It should be noted that mortality risk factors in this study are synonymous 
with the term “variables”. The participants in the study are referred to as patients or 
residents, which are synonymous.  
Based on the literature review, selected variables were identified for evaluation of 
their predictive value in determining heart failure mortality in residents of SNF. These 
variables were evaluated simultaneously using multivariate regression methodologies to 
quantify their predictive value in the SNF care setting. Methodologies included survival 
analysis with calculation of hazard ratios that are described later in this chapter.  
Dataset Quality 
 
Since the data for this study were extracted from existing RAI-MDS databases 
across multiple SNFs, the following criteria were used to select organizations from which 
to extract their data so as to ensure dataset quality: (a) data must come from a facility 
organization that has a regional operational leadership, (b) R.N.’s completing the RAI-
MDS 3.0 instrument must have had proper training and credentialing, (c) the organization 
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has stable facility leadership, (d) the organization has engaged the services of a data 
analytics firm that cross validates the data for consistent item response, (e) the 
organization utilized current standards of practice, and (f), the facility must be operated 
by one leadership team.   
Based on these criteria, a multi-facility organization was selected for the data 
sample. This facility operated 24 SNF’s in the Midwest, had a stable regional and facility 
leadership with consistent direction, and was respected as quality facility operators by the 
state licensure and certification agency. This organization employed R.N.’s that were 
trained on completion of the RAI-MDS and credentialed by the American Association of 
Registered Nurse Assessment Coordination (2016) which designates them as Registered 
Nurse Assessment Coordinators (RNACs). These R.N.s were required by law to indicate 
that the information contained in the assessment was accurate and represents the patient 
and are presumed to understand the nuances of the instrument completion process. This is 
important since responses are not always self-evident and must be consistent with the 
RAI-MDS 3.0 User Manual definitions and criteria.  
 All the completed assessment instruments were screened by proprietary software 
for accuracy, completion, and consistent item response. Since completed assessments are 
forwarded to the state and CMS, the software allows the RNACs to correct or improve 
their responses on the instruments based on this software’s feedback to obtain the best 
description of the patient at that point in time, thereby improving the accuracy of the 
assessment.  
This organization utilized national standardized professional care guidelines. 
Further, the SNFs in this organization did not use temporary staffing, and therefore, may 
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have greater consistency in care delivery and documentation. It is believed that the 
deliberate process of selecting this organization and the number of SNFs that drawn from 
enhanced the internal and external validity of the study and thereby increases the 
potential to generalize the results of this study to other SNFs in the United States. 
Instrument Reliability and Validity:  RAI-MDS 3.0 
 
The RAI-MDS 3.0 instrument and user manual were extensively tested by CMS 
prior to implementation in the SNF care setting. RAND Health Corporation conducted an 
extensive evaluation of the validity and reliability of the updated RAI-MDS 3.0 
instrument published in 2008 (Saliba & Buchanan, 2008). The intent of updating the 
RAI-MDS from the 2.0 to 3.0 version was to bring voice to the patient (resident) and 
better capture the care needs of this population. This third version increased focus on 
patient-centered concerns and needs.  
Assessment items on the RAI-MDS 3.0 instrument were tested for interrater 
reliability. Beta testing revealed kappa statistics to be very good to excellent for both the 
gold-standard to gold-standard nurse assessment and the gold-standard to facility-nurse 
assessment comparisons. Generally, the reliability statistics were higher than those 
published for RAI-MDS 2.0 version, particularly when the facility nurse performing the 
assessment was compared to the gold-standard nurse’s documentation (Saliba & 
Buchanan, 2008).  
National validation testing for MDS 3.0 for the cognitive, depression, and 
behavior items showed significantly higher agreement with criterion measures than did 
MDS 2.0 items collected on the same residents. These categories were tested specifically 
as they were new to the instrument and incorporated reliable and validated instruments 
44 
 
such as the PHQ-9 (Patient Health Questionnaire - 9, Resident Mood Interview) and 
BIMS (Brief Interview for Mental Status) assessment tools. 
The RAI-MDS 3.0 has 17 defined demographic and clinical assessment sections 
covering categories such as patient identification, cognition, mood, behavior, functional 
status, pain, skin integrity, nutritional status, active diagnoses, and essential components 
for planning care for the patient. A link to this instrument is found at: 
https://downloads.cms.gov/files/mds-3.0-rai-manual-v1.17.1_october_2019.pdf. 
When the RAI-MDS 3.0 instrument is completed, specified response factors can 
trigger up to 20 additional high-risk assessment protocols, defined as Care Area 
Assessments (CAA). CAA examples include delirium, ADL functional potential, 
nutritional status, pain, and others. These CAA are completed by the interdisciplinary 
team and augment the process of formulating a comprehensive individualized care plan.  
Study Database 
 
The database for this study was in an Excel spreadsheet obtained from the 
multifacility SNF organization that included the RAI-MDS assessments of all patients 
diagnosed with heart failure (HF) in the midwest SNFs in 2013-2014  The data file 
contained 10,336 RAI-MDS 3.0 completed instruments representing 3208 HF patients. 
Each patient’s assessment data were noted on a separate row of the database with 
columns representing each RAI-MDS 3.0 assessment component. Data included 
assessments where the patient had a primary or secondary diagnosis of heart failure and 
excluded all other patient assessments if the HF diagnosis was not present. The two-year 
timeframe was selected to adequately capture a sufficient sample size that would include 
the event of expiration for many subjects based on literature describing HF mortality .  
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Approval to use the database was obtained from the SNF organization and 
documented in a letter of support. The organization was provided a detailed description 
of how the data would be maintained according to HIPAA and corporate compliance 
expectations. Patient data utilized for the study was de-identified prior to analysis.  
 Protection of this database was on a password protected computer and will be 
retained for five years after completion of this study for additional analysis if desired, and 
then the data will be destroyed. The rationale for keeping the data is to allow other 
potential statistical approaches to be applied as deemed useful by this researcher in 
furthering the work of improving the quality of life and care for HF patients in SNFs.   
Prior to obtaining the data, an Institutional Review Board (IRB) application was 
submitted to Marquette University to determine whether the proposed research 
methodology was ethically sound. The IRB approved the study in 2015 and a continuing 
approval was obtained prior and subsequent to initiation of the study and data analysis. 
Data were evaluated and cleaned to produce a data set that met the requirements 
of this study. Patients who did not have HF as one of their diagnoses were removed from 
this database. While the sampled subjects have other diagnoses, all participants in this 
sample had an underlying primary or secondary diagnosis of heart failure. The RAI-MDS 
3.0 instruments obtained were all complete with no known missing data as the analytic 
files. CMS submission software does not allow incomplete assessments to be submitted. 
Participants in this database included patients that were: a.) initially admitted from a 
hospital to the facility, b.) had two or more assessments completed, and c.) were living at 
the end of the study or had expired prior to the end of the study time period or were 
discharged to the community.  
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Study Variables  
 
 As noted in Chapter Two, variables shown to predict HF mortality were identified 
through a careful and deliberate review of published heart failure mortality models. 
Variables present within the RAI-MDS 3.0 instrument that have been shown to correlate 
with heart failure mortality were included in the present study. They include: 
1.  Hospital Admission (study entrance). As all subjects in the database were 
admitted initially after an acute hospital stay. Subjects were evaluated from 
the first full RAI-MDS 3.0 assessment occurring after January 1, 2013. This 
assessment may not represent the first admission to the SNF. This variable 
was captured from the RAI-MDS 3.0 and signified the starting point for each 
subject in the study. Subjects were also started in the study beginning with an 
annual assessment if previously residing in the facility. This was represented 
on the RAI-MDS instrument as data point A 0310 B 01 or A0310 A 3. 
2. Expiration. Expiration was defined as the death of a subject and reflected as 
the end of the assessment cycle. If a subject was discharged to an acute care 
facility and was expected to return but does not return within 14 days, the 
subject was counted as expired. Each subject either continued to be living at 
the end of the study or had expired. This was represented on the RAI-MDS 
instrument as data point A 0300 F 12. Therefore, the event of death is defined 
as either death in the facility or a discharge to an acute hospital with no 
readmission within 14 days.  
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3. Age. Age was captured in the following manner: (a) 65 years old to 84 and (b) 
85 and older. This is represented on the RAI-MDS instrument as data point A 
0900.  
4. Gender. This variable was coded as either male or female. This was 
represented on the RAI-MDS instrument as data point A 0800.  
5. Number of hospitalizations since initial SNF admission. Future hospital 
admissions were captured and identified as a readmission to the facility. This 
variable was represented in the following manner: one additional hospital 
admission after initial admission to the SNF represented by readmisson. This 
was represented on the RAI-MDS instrument as data point A 1800 03 for each 
admission.  
6. Comorbidities. Total number of comorbid conditions were evaluated in this 
variable. Comorbidities are diagnoses that are present for each patient and 
captured from the medical record to the RAI-MDS 3.0. These were 
represented in the following manner: three (3) or more comorbid diagnoses. 
This variable was utilized as the literature indicates that greater comorbidity 
increases mortality in this population (Murad et al., 2015). These were 
represented on the RAI-MDS instrument as those listed in data points I 10100 
– I8000. 
7. Diabetes Mellitus (DM). The presence of a diagnosis of diabetes mellitus was 
captured as either present or not present. This was represented on the RAI-
MDS instrument as data point I 2900. 
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8. Hypertension. The presence of a diagnosis of hypertension was captured as 
either present or not present. This was represented on the RAI-MDS 
instrument as data point I 0700. 
9. Reduced renal function. While biological serum laboratory results are not 
captured on the RAI-MDs, this variable is specifically noted on the RAI-MDS 
3.0 instrument as renal insufficiency, renal failure, or End Stage Renal 
Disease (dialysis). The presence of one of these diagnoses indicated a reduced 
renal function. This was represented on the RAI-MDS instrument as data 
point I 1500.  
10. Dyspnea. Shortness of breath with exertion, when sitting, and when lying flat 
was used to define dyspnea in this study. Presence of one or more of these 
indicates the presence of dyspnea in the subject. This was represented on the 
RAI-MDS instrument as data point J 1100 A and/or B and/or C.  
Data Analytical Methodology and Procedures 
 
This study used data collected from January 1, 2013 through December 31, 2014. 
During this two year time period, patients were entered in the study as they were admitted 
to the SNF for the first time after an acute hospital stay within those years, or began the 
study at their first full RAI-MDS 3.0 assessment if already a patient. Therefore, the study 
began January 1, 2013 and ended December 31, 2014. 
Discrete survival analysis was the statistical method employed in this study. 
Survival analysis is the study of the distribution of periods of time beginning with a 
defined starting period and measured over time until a terminal event occurs (Allison, 
2010). Survival analysis asks the question of whether and when the event of death 
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occurred (Singer & Willett, 2003), which is the intent of this study. Therefore, the 
researcher must ask what target event is occurring, define a beginning of time for the 
study, and a metric that represents the passage of time.  
The statistical analysis was a multistep process that initially performs logistic 
regression, modeling whether the patient died within a window of time at 60, 90, 120, 
and 180 days following the first full MDS assessment as the logical probable death 
window. The first analytical step in this process was defining the time of origin for each 
patient that signifies the beginning of the study. The time of origin was defined as the 
first full RAI-MDS 3.0 assessment completed in year 2013 or 2014, either as an annual 
assessment or a new admission assessment. This was captured from A 310 as either A 01 
or 03. It may occur at any time during the study period.  
For the purpose of the logistic regression analysis, different primary analytic data 
files were created from the original data set as follows. Each row in a primary analytic 
file, that is, each new case record in the Excel spreadsheet, was generated by a full MDS 
assessment for which the life-death status can be measured at two, three, four, and six 
months after admission. Each new record case does not represent a patient but rather an 
uninterrupted stay of a patient in the SNF.  
Stepwise methods were employed to develop predictive models for proximity to 
death using different MDS risk factors as explanatory variables. Subsequent to that 
analysis, discrete survival analysis and Cox proportional hazards models were explored. 
Unlike logistic regression, which examines the overall probability of an event without 
regard to the timing of that event, survival analysis allows the examination of the 
longitudinal progression of the probability that the event (i.e. death) occurs (Allison, 
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2014). Hence, analysis occurs in terms of the hazard at a point in time, namely, the risk of 
the event of death occurring per unit of time elapsed, given that the patient has survived 
up to that time. The hazard function expresses the hazard of death as it changes over time 
and was modeled using the MDS risk factors. 
The statistical program SAS was used to analyze this data set. Survival analysis 
was performed using survival time as the dependent variable and exploring the 
explanatory variables impact on the hazard rate function. A special feature of survival 
data, called censoring, indicates that the event of death is not observed for a number of 
patients, but instead we know that it has not yet taken place, due to the study ending, or to 
discharge for reasons other than death. In most survival analysis methods, as in the Cox 
proportional hazard models, the survival time is assumed to be a continuous variable.  
In this analysis, it was reasonable to split the two-year observation period of the 
study in several time intervals and to consider discrete-time survival methods (Allison, 
2014). More explicitly, each survival time then represents a set of indicators of whether 
or not a patient failed in each time unit until a person either experiences the event of 
death or is censored. This allows the researcher to perform the discrete time survival 
analysis with standard logistic regression procedures. The methodology included the 
extra effort of entering the data in a “long person-period” format so that each patient’s 
survival history is broken down to a set of discrete time units. For example, if a patient 
dies at the fourth time unit, four different observations (i.e. rows in the person-period data 
set) will be created. For the fourth observation, the dependent variable will be coded “1” 
indicating death, and for the previous three observations, it will be coded “0”. Hence, the 
patient’s one record will yield four records in the person-period format. Then the 
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researcher can estimate a logistic regression model predicting whether the death event did 
or did not occur in each time unit.  
Specifically, estimates were generated for as many probabilities as time units. 
That is, for each time unit, an estimate will generate the conditional probability that a 
patient will experience the event of death at that time unit, given that the patient did not 
experience the event prior to it. These conditional probabilities are the fundamental 
parameters of this analytic process. Analysis will estimate their values and investigate 
their dependence on the MDS risk factors (i.e. explanatory variables). This is referred to 
as the set of these conditional probabilities as the discrete-time hazard function. Figure 2 
represents the methodological modeling employed in this study. 
Figure 2: Modeling Heart Failure
 
Methodological Rigor  
 
 As the data set is comprised of historical data obtained in a methodologically 
rigorous process following the RAI-MDS 3.0 user’s manual, it was presumed that the 
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dataset met the standard for quality quantitative research. This researcher maintained the 
rigors of the process of analyzing the data through a careful and conscientious method 
when sorting the database to extract only the variables and information that were 
pertinent to this study. The data were organized in an Excel spreadsheet and columns of 
data not needed for this analysis were hidden but maintained for other purposes if needed.   
 It is important to assure statistical validity in the process of evaluating the data 
output (Polit & Beck, 2017). Conclusions reached must be valid inferences from the 
analysis and deployment of appropriate statistical methods. In conducting this research, 
the internal validity must also be evaluated to assure that the relationships among 
variables are truly due to their unique interactions rather than caused by other variables.   
 Construct validity of the instrument allows the researcher to infer from the study 
results and determine their outcome value (Polit & Beck, 2017). It is believed this study 
had construct validity and was unbiased in producing valid reliable results. Lastly, 
external validity concerns whether study results can be generalized to other setting and 
populations. As the data instrument is consistent across all SNF’s and the variables were 
based on published predictive models, the generalizability of the findings to other SNFs 
is purported to be good. This researcher also engaged the services of a statistician who is 
Ph.D. educated and experienced in working specifically with this database and skilled in 
logistic regression and survival analysis. Together with the statistician, this researcher 
properly organized and analyzed the data using procedures defining the episodic data for 
each subject and evaluating explanatory variables from pertinent sections of the RAI-
MDS 3.0 instrument.  
 
53 
 
CHAPTER IV: RESULTS 
 
 The purpose of this study was to analyze specific variables to determine their 
relative risk of causing mortality in patients with heart failure who resided in skilled 
nursing facilities during a two-year period. Analysis was performed to determine the 
trajectory of mortality for the study sample at 60, 90, 120, and 180 days. Table 2 reflects 
the number of patients who died and those who were alive or censored at each of the time 
periods over the two-years of data collection. Since patients were admitted at various 
points throughout this two-year period, the number of patients at 60, 90, 120 or 180 days 
diminished accordingly. Consequently, the number of patients alive at 60 days (1,827) is 
larger than at 90, 120, and 180 days. As outlined in Table 2, the number of participants 
who died increased over time, with 337 participants dying within 60 days, and 526 who 
died dying within 180 days. 
 
Table 2: Number of Patients Alive vs. Death at 60, 90, 120, and 180 Days 
Days Eligible Patients  Patients Who Died Patients Who Didn’t Die 
60 1,827 337 1,490 
90 1,640 398 1,242 
120 1,483 447 1,036 
180 1,283 526 757 
 
 
 Using the data analysis software SAS, the PROC PHREG (Cox Proportional 
Hazard Modeling) procedure was used to compare the survivor functions across the two 
groups of patients in the analysis, those that died, and those that survived or were 
censored for the given period of time. PROC PHREG is an analytic procedure that 
implements the Cox model to generate the hazard ratio estimate of a given variable. The 
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output reflects the results of the statistical survival analysis and logistic regression 
methodologies. For each of the variables, survival product limit curves were created and 
analyzed. Table 3 presents the model of the analysis that evaluated the study variables to 
determine the Cox proportional hazard function of each variable. In survival analysis, 
using the Cox proportional hazard model, the interpretation of the analytical output is the 
hazard ratio. The hazard is described as the expected number of deaths or events in a unit 
of time, or, the probability of the event happening in that time interval. 
Survival Analysis Model Results 
 
Table 3. Model Results 
Analysis of Maximum Likelihood Estimates 
Parameter 
Log Rank 
Statistic 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square Pr > ChiSq 
Hazard 
Ratio 
Hospital 
Readmission 
52.528 0.27976 0.07669 13.3069 0.0003 1.323 
Reduced Renal 
Function 
21.919 0.17151 0.07764 4.8800 0.0272 1.187 
Hypertension -40.043 -0.39752 0.09490 17.5476 <.0001 0.672 
Dyspnea ( short 
of breath) 
45.0 0.25047 0.07682 10.6320 0.0011 1.285 
Diabetes -33.0 -0.14782 0.08232 3.2246 0.0725 0.863 
Age 65 to 84 -40.0 -0.64531 0.19406 11.0583 0.0009 0.524 
Age 85 and 
greater 
105.66 0.60326 0.07872 58.7251 <.0001 1.828 
Male Gender 6.8002 0.14717 0.07819 3.5425 0.0598 1.159 
3+ Diagnoses –   26.684 0.29660 0.10432 8.0842 0.0045 1.345 
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Table 3 represents the Cox proportional model results. The parameter estimate 
along with the standard error and Chi-Square value are shown. The PR> ChiSq represents 
the p value for each factor. The hazard ratio for each factor is shown in the last column 
on the right. Negative parameter estimates and those factors with p values greater than 
0.05 are not significant (hypertension, diabetes, age 65-84, male gender). As observed in 
the table, five of the nine variables were significant. The following section presents the 
analysis for each of these variable and includes the product limit survival estimate curves, 
the number of deaths, and the associated risk of mortality. 
Hospital Readmission 
 
Hospital readmission was defined as those patients who were previously admitted 
to the SNF, subsequently hospitalized, and then re-admitted to the SNF for care. For this 
variable, there were 728 who were hospitalized and returned to the SNF and 2,480 
patients who were not hospitalized. For those hospitalized, there were 290 (39.8%) deaths 
and 461(18.5%) deaths in the group that were not hospitalized. As noted on Figure 3 that 
follows, there is visual evidence of the hospitalization and readmission effect. The 
survival curve for those hospitalized and readmitted to the SNF declined more steeply. 
The graph indicates plus signs whenever there are censored projected observations when 
the event of death did not occur.  
The x axis is segmented for modeling purposes into time increments of 200 days 
for each segment for the two-year observation study (maximum observations of 730 days, 
therefore graph reflects 800 days). Along the x-axis, the number of patients still at 
risk (not yet dead or censored) are indicated separately for each patient group in the 
model. The blue curve represents the patients who did not have a hospital readmission 
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and the red indicating those that did. The y axis represents that model’s proposed survival 
probability curve for each group.  
Figure 3: Survival Curve for Hospital Readmission 
 
Note: Hospital Readmission is “re-entry”.  0 = not hospitalized nor readmitted (blue); 1 = 
readmission (red) 
 
For the readmission group, the log-rank statistic is 52.528. The log-rank test is the 
most widely used test for differences in the survivor function. The log-rank test can be 
represented as the sum of the deviations of observed numbers of events (i.e. deaths) from 
expected numbers of events, where the summation is over all unique event times in both 
groups. The Wilcox test differs from the log-rank test only by the presence of some 
weights. That is, it is a weighted sum of the above deviations, giving more weight to the 
early times than to the late times. The p-values for both tests are significant at p < 0.0003. 
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The hazard ratio for this variable is 1.323 indicating that readmission increases the risk of 
mortality by 32.2% for those with HF in SNFs. 
Reduced Renal Function  
  
Reduced Renal Function is defined as the patient having a diagnosis of renal 
failure, renal insufficiency, or was on dialysis, reflecting total renal failure. For this 
variable, there were 1,110 patients who had reduced renal function and 2,098 who did not 
have reduced renal function. For those with reduced renal function, there were 268 deaths 
(24%) and 483 (23%) deaths for those without reduced renal function.  
 
Figure 4: Survival Curve for Reduced Renal Function 
 
 
Note.  Dialysis on graph indicates Reduced Renal Function. 0 = no reduced renal function 
(blue); 1 = reduced renal function  (red) 
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As can be noted on Figure 4, there is a visual difference in the effect for both 
groups. The survival curve for those with reduced renal function (red indicators) declines 
quickly then resumes a more steady decline with plus signs noting those censored. Along 
the x-axis, we have noted the number of patients in the model still at risk (not yet dead or 
censored) indicated separately for each patient group. For reduced renal function, the log-
rank statistic is 21.919. The p-values are significant for both tests at < 0.0272. The hazard 
ratio for this variable is 1.187 indicating that reduced renal function increases the risk of 
mortality by 18.7% for those with HF in SNFs. 
Hypertension 
 
This variable reflects whether the patient had a diagnosis of hypertension or not. 
There were a total of 2,719 patients with hypertension and 489 patients that did not have 
hypertension. For those with hypertension, there were 610 (22%) deaths with 141 (29%) 
deaths if  hypertension was not a defined diagnosis.  
As can be noted on Figure 5, there is visual evidence of the hypertension 
effect. The survival curve for those with normal function (no hypertension- blue) declines 
more rapidly than those with the diagnosis. The log-rank statistic is -40.043 for the 
hypertension group. As the parameter estimate is negative, the results indicate that this 
variable is not significant in predicting the mortality outcome for this variable.  The p-
values for both tests are < 0.0001 with a negative parameter estimate. The hazard ratio for 
hypertension is 0.672. 
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Figure 5: Survival Curve for Hypertension 
 
Note: 0 = no hypertension (blue); 1 = hypertension (red) 
 
Dyspnea 
 
Regarding the variable of dyspnea, or shortness of breath, there were a total of 
1,575 patients who had a diagnosis of dyspnea and 1,633 patients who did not. For those 
having dyspnea, there were 393 deaths (24.95%) compared to 358 (21.92%) deaths for 
those lacking the symptom of dypsnea. As noted in Figure 6, there is a minimal 
difference in the effect for both groups. The survival curve for those with a diagnosis of 
dyspnea declines at a slightly different and faster rate and progression than those without 
that diagnosis. The log-rank statistic is 45 for the those with a diagnosis of dyspnea. The 
p-values for both tests are significant at < 0.0011. The hazard ratio for this variable is 
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1.285 indicating that those with a diagnosis of dyspnea have a 28.5% greater chance of 
mortality than those that do not have the diagnosis. 
 
Figure 6: Survival Curve for Dyspnea 
 
Note: Short breath indicates dyspnea. 0 = no dyspnea (blue); 1 = dyspnea (red) 
 
Diabetes 
 
The variable of having the diagnosis of diabetes was also analyzed. There were 
1,490 patients who had a diagnosis of diabetes and 1,718 patients who did not. For those 
having diabetes, there were 322 deaths (21.61%) and for those not diagnosed with 
diabetes, there were 429 deaths (24.97%). As can be noted on Figure 7, there is not a 
signficant difference in the effect for both groups. The survival curve for those with a 
diagnosis of diabetes declines about the same as those without that diagnosis initially and 
then declines slightly more rapidly over time.   
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As the parameter estimate is negative, the results indicate that this variable is not 
significant in predicting the mortality outcome. The log-rank statistic is -33 for the those 
with a diagnosis of diabetes. The p-value for both tests is < 0.0725 which indicates that it 
is not statistically significant. A p-value higher than 0.05 indicates that this is not 
statistically significant. The hazard ratio for this variable is 0.863 indicating that having a 
diagnosis of diabetes may reduce the risk of mortality. 
 
Figure 7: Survival Curve for Diabetes 
 
Note. 0 = No diabetes (blue), 1 = diagnosis of diabetes (red)  
 
Age 65 to 84   
 
The variable of age greater than 65 years to 84 years old was analyzed. This 
included those patients who were 65 and older yet not 85 years old. There were 2855 
patients who were 65 years and under age 84 and 353 who were not yet 65 years old. For 
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those that were between 65 and 84,there were 722 deaths (25.29%) and for those under 
age 65,  29 (8.22%) deaths. As can be noted on Figure 8, there is a significant difference 
in the effect for both groups. The survival curve for those under 65 years old declines at a 
significantly slower rate and appears to project minimal deaths than the progression of 
those 65 and older. The log-rank statistic is -40 for the those 65 and older. As the 
parameter estimate is negative, the results indicate that this variable is not significant in 
predicting the mortality outcome for this variable. The p value is 0.0009. The hazard ratio 
for this variable is 0.524. 
 
Figure 8:  Survival Curve for Age 65 to 84 
Note. Age 65 to 84 = 0 (blue); Under 65 = 1 (red) 
Age 85 and greater 
 
The variable of age greater than 85 was analyzed to determine predictive 
mortality for this population. There were 1,072 patients who were age 85 and older and 
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2,136 who were 84 and younger. For those 85 and older, there are 368 deaths (34.33%) 
and for those 84 and younger, 383 deaths (17.93%). As can be noted on Figure 9, there is 
a significant difference in the effect for both groups. The survival curve for those 85 
years and older (red indicators) declines at a significantly faster rate and progression as 
those under 85 years old.  The log-rank statistic is 105.66 for the those 85 and older. The 
p-values for both tests are significant at < 0.0001. The hazard ratio for this variable is 
1.828 indicating that being 85 or older increases the risk of mortality by 82.8%. 
 
Figure 9: Survival Curve for Age 85 and Over
 
Note: 0 = under 85 (blue); 1= 85 age and older (red)  
Gender 
 
This variable was analyzed by indicating whether the patient was male or not 
male (female). There were a total of 1,282 patients who were of male gender and 1,925 
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who were of female gender. For the male gender, there were 281 deaths ( 21.92% ) and  
470 deaths (24.42%) of female gender. As can be noted on the graph, there is no 
significant difference in the effect for both groups. The survival curve for males declines 
at nearly the same rate and progression as those of female gender. The log-rank statistic is 
6.8002 for the male gender. The p-values for both tests are 0.0598. A p-value higher than 
0.05 indicates that this is not statistically significant. 
Figure 10: Survival Curve for Gender 
 
Note: 0 = female gender (blue); 1 = male gender (red) 
 
 
Three or more diagnoses 
 
 
This variable reflects patients having three or more diagnoses compared to those 
having less than three. There were 568 patients with three or more diagnoses and 2,640 
who had less than three diagnoses. For those with three or more diagnoses, there were 
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147 deaths (25.88%) and there were 604 deaths in patients with  less than three diagnoses 
(22.9%). As noted in Figure 9,the  survival curve for those with 3 or more diagnoses 
declines at a slightly faster rate and progression as those with less than 3 diagnoses. The 
log-rank statistic is 26.684 for the those with 85 and older. The p-values for both tests are 
significant at < 0.0001. The hazard ratio for this variable is 1.345 which indicates a 
34.5% greater risk of mortality if the patient has 3 or more diagnoses. 
 
Figure 11: Survival Curve for Three or More Diagnoses 
 
Note : 0 = less than three diagnoses (blue); 1 = 3 or more diagnoses (red)   
 
 
 
 
 
CHAPTER 5: Discussion 
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 Of the nine variables evaluated using statistical survival analysis modeling, five 
variables predicted increased risk of mortality in the SNF heart failure patient. Hospital 
re-admission, presence of renal disease, presence of dyspnea, age 85 and older, and 
having greater than three diagnoses indicated increased risk of mortality. Four variables 
were not significant in predicting increased mortality risk. Those were diagnosis of 
diabetes, diagnosis of hypertension, being age 65 to 84, and male gender.  
Predictive Variables  
 
Hospital Readmission 
 
The first predictive variable was hospital re-admission. Almost all SNF patients 
are initially admitted following a hospital stay. However, this variable represented a one- 
time rehospitalization during the patient’s SNF stay. This finding is supported by other 
studies which have found that declining patient health status caused hospitalization and 
ultimately mortality. Repeated hospital admission is indicated as a strong predictive 
variable (Eapen et al., 2013; Yancy et al., 2013). While the study patients may have had 
multiple hospital admissions, the present study analysis only captured one hospital 
readmission (binary variable), and therefore, does not capture the same patient having 
multiple re-admissions during their SNF stay.  
Multiple hospital admissions due to exacerbation of the disease process are 
indicative of declining health. It is known that 83% of SNF patients are rehospitalized at 
least once per year and 43% at least four times each year (Heidenreich et al., 2011). 
Capturing multiple hospital readmissions could have provided additional mortality risk 
data. The hazard ratio for this variable was noted to be 1.323, or having at least one 
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hospitalization during the patient’s SNF stay would increase the risk of mortality by 
32.3% compared to their peers in the sample. Further, providing palliative care may 
reduce hospitalization as patients’ end of life wishes are then honored.  
Multiple studies indicate that hospitalization of HF patients increases the risk of 
mortality (Foebel et al., 2013; Kommuri et al., 2012; Metra et al., 2007). The present 
study assessing one hospital re-admission aligns with the previous studies indicating 
increased mortality risk. While other studies evaluated the impact of hospitalization, only 
one study evaluated this factor in the SNF setting. Foebel et al. (2013) evaluated 
predictors of SNF HF patient hospitalization and resultant mortality and found similar 
results. These findings add further support that hospitalization increases the risk of 
mortality for HF patients.  
Reduced Renal Function 
 
 In the present study, renal disease was classified as renal insufficiency, renal 
failure, and/or being on dialysis. As renal disease is a comorbid condition prevalent in the 
HF population, it was evaluated to determine the significance of its impact on mortality. 
Prior studies have identified renal disease as a risk factor for mortality in this population 
(Chaudhry et al., 2013; Chyu et al., 2014; Fonarow et al., 2005; Giamouzis et al., 2011; 
Levy et al., 2006; Murad et al., 2015; Ouwerkirk et al., 2014; Rahimi et al., 2014; Senni 
et al., 2013; and Yancy et al., 2013). In the Murad et al. (2015) study, the comorbid 
condition of renal disease increased the risk of mortality by 32%. Whereas, in the present 
study, the mortality risk hazard ratio was lower at 18.7%, However, Murad and 
colleagues assessed mortality risk at the inception of a HF diagnosis of community-based 
participants which may explain the decreased risk in the present study of SNF patients. 
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Their patient population was evaluated based on a three-year retrospective review of 
clinical conditions that may have impacted the diagnosis of HF. As most diagnoses 
indicated in the medical record are captured from the previous acute hospital stay, the 
patients in the present study may or may not have a physician documented diagnosis of 
reduced renal function as the SNF attending physician is generally not the community 
primary physician. Therefore, the diagnosis of reduced renal function may not be 
captured on the RAI-MDS.  
Dyspnea 
 
Having dyspnea, or shortness of breath, increased the likelihood of mortality in 
the present study. The hazard ratio for dyspnea was 1.285 signifying that this group of 
patients have a 28.5% greater likelihood of mortality than those in the study population 
who did not have that coded condition. This finding was similar to the prospective study 
by Senni et al. (2013) that identified risk factors to create a mortality risk tool. In their 
study, the presence of a diagnosis of COPD had an odds ratio of 1.20 with a 95% 
confidence internal.  
While this researcher expected a greater hazard ratio for this variable, it may be 
diminished due to data capture limitations of physician coding on the medical record as 
previously described. Further, in the present study, the variable COPD as a diagnosis was 
not used. While dyspnea may be present in the HF population due to COPD, or other 
comorbid conditions, evaluating the presence of COPD may be useful in mortality risk 
prediction.  
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85 Years Old and Older 
Not surprising, being eighty five (85) years and older has an increased risk of 
mortality. The hazard ratio of 1.828 for those 85 and older increased the mortality risk by 
82.8% compared to all those in the study. Therefore, age appears to play a significant role 
in predicting mortality in this population. This finding is supported by studies previously 
discussed in the literature review that found age to be a significant predictor of mortality. 
Pocock et al. (2013) conducted a meta-analysis and found that age was one of the 
strongest predictors of mortality in HF patients. Jurgens et al.(2015) also found that as 
individuals age, the number of comorbid conditions increase as does mortality. Rahimi et 
al. (2014) evaluated 43 risk models and identified that age and gender were significant 
predictors of mortality. Betihavas et al.( 2015) also identified a HR of 1.07 for each 10 
year increase in age. In the present study, increased age greater than 85 demonstrated a 
HR of 1.828. 
Three or More Diagnoses 
 
 This variable was selected for the study to represent, by proxy, the indication of 
frailty in this population as supported by Jurgens et al. (2015) and Murad et al., 2015. 
Betihavas et al.( 2015), Rahimi et al. (2014), and Senni et al.(2013) identified that 
comorbid conditions increased the risk of mortality. Murad et al. (2015) in their 
evaluation of the Cardiovascular Health Study HF participants examined the impact of 
comorbidities on the mortality of that population. Sixty percent (60%) of those patients 
had three or more comorbidities which contributed to their mortality risk.  
The RAI-MDS assessment instrument does not have a specific variable that 
represents frailty which would signify a declining health status of the patient. To address 
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this, three or more comorbid diagnoses defined this variable. It is not uncommon to have 
significantly more diagnoses identified in the medical record. Furthermore, only specific 
diagnoses are indicated for inclusion on the RAI-MDS 3.0 instrument and thereby limits 
the potential to identify all that may be present. The hazard rate in this study for three or 
more diagnoses was 1.345 which is similar to other studies (Betihavas et al., 2015; 
Rahimi et al., 2014; and Senni et al.,2013). Therefore, this  proxy variable appeared to be 
useful in representing frailty in this study. This study indicated that having three or more 
diagnoses increased the risk of mortality by 34.5% compared to their peers in the study 
group.  
Non-Predictive Variables 
 
 The following variables were not significant in predicting mortality in this study 
population. While it was expected that these variables would be significant in increasing 
the mortality risk for HF SNF patients, the study results did not demonstrate such risk.  
Hypertension 
 
In the present study, the model’s survival curve indicated that those without a 
diagnosis of hypertension had a more significant decline leading to mortality than those 
with the diagnosis. This is perplexing since hypertension is a major etiologic risk factor 
for the development of HF (Yancy et al.(2013) and it is included in HF risk models as a 
predictive variable (Fonarow et al., 2005; Levy et al., 2006; and Senni at al. 2013).   
A possible explanation of this is that patients in the study , were being treated for 
hypertension and therefore more clinically stable. It is known that about 25% of patients 
in the community that have hypertension do not comply with their prescribed medication 
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regimen or are not adequately treated (Yancy et al, 2015). Alternately, patients may have 
had hypertension but it was not indicated as a primary diagnosis by the attending 
physician, or that patients may have had hypertension yet not been diagnosed at the point 
of assessment. Another possible explanation is that roughly half of the patients have 
diastolic HF which is generally due to ventricular stiffening causing fluid balance issues, 
some of which are hypertensive. Because of this, further analysis is required to determine 
the viability of hypertension as a mortality predictor and to rule out alternative causes for 
this confounding finding.  
Diabetes 
 
Diabetes is a major etiologic risk factor similar to hypertension that causes 
microvascular damage impacting the mortality of those with HF (Shindler et al., 1996). In 
the Murad et al. (2015) study, the presence of diabetes in the community setting for 
adults 65 and older had a hazard ratio of 1.64. While it might be expected that this 
variable would be significant in this study, the results indicated that comparing those with 
and without the diagnosis of diabetes showed no significant difference between the 
groups. Similar to the findings related to hypertension, it is possible that patients with 
diabetes who are admitted to the SNF are being adequately treated and more closely 
monitored than if they were still living in the community. Another possible explanation is 
that the patient may not have had the diagnosis indicated in the medical record by the 
attending physician, or that the patient may not have yet been diagnosed. Based on this, 
further examination of the role of diabetes care in SNF should be examined, since proper 
management may have a protective effect.  
Age 65 to 84  
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 The influence of age was analzyed using two distinct groupings; the patient 
population aged 65 to 84, compared to those patients less than 65 years old. The mortality 
risk model survival estimates showed a somewhat linear decline of those in the 65 to 84 
compared to those younger than 65 who showed more modest decline of projected 
mortality. This is expected and it supports findings of Betihavas et al. (2015) that 
identified a HR of 1.07 for each 10-year increase in age.  
 One possible explanation for the reduced mortality for this younger age group is 
that a majority of SNF admissions are admitted for short term rehabilitation. Those 
patients, while they may have a diagnosis of HF, are in the SNF for rehabilitation and 
return home after a brief stay. Therefore, the older the patient, the greater the risk of 
mortality. This younger age group variable is not significant in predicting mortality in the 
HF SNF population.  
Gender 
 
 Gender was evaluated in this study as prior research suggested that being of male 
gender increased the risk of mortality for those with HF (Chyu, et al. (2013). Klempfner, 
et al. (2014) found the opposite in that female patients had a higher risk of mortality. 
However, the present study indicated that there was not a significant difference in gender 
relative to the risk of HF mortality in the SNF setting. As female patients comprise the 
majority of the SNF population, it is possible that males with HF have died in the 
community rather than in the SNF. Further evaluation of the gender variable is warranted 
as this study showed no significant difference.   
Theoretical and Practical Findings of Implications 
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 Of the nine variables selected for this study, five were significant in identifying a 
higher risk of mortality for SNF HF patients. These variables were selected based upon 
their significance and predictive value in multiple heart failure mortality risk models in 
other studies. Once examined through survival analysis and modeling, some variables 
became significant in predicting higher risk of mortality for those with HF residing in 
SNFs. Theoretically, a heart failure mortality risk model could be created from these 
variables with eventual development of a risk tool. As the variables selected for this study 
are included in the RAI-MDS 3.0 instrument and obtained through routine assessment, 
the ease of risk modeling could be put into place with minimal effort. Ideally, an 
additional assessment, RAI-MDS Care Area Assessment, could be generated 
electronically to identify potential additional risk assessment for the patient if triggered 
on the RAI-MDS.  
Mortality risk identification has practical implications in the SNF setting as those 
patients are already compromised medically and physically. Creation of a risk model and 
tool would be useful for SNF nurses and other practitioners. Having the ability to utilize 
known mortality risk variables in a model that is directly obtained from the required 
assessment instrument could be highly valuable. Eliminating additional assessment data 
capture from other sources would facilitate an easily accessible risk assessment tool. 
Once mortality risk is identified for each patient, palliative care discussion could occur 
regarding treatment and quality of life preferences. As part of that discussion, nurses 
might consider the implications of how that information may affect the patient and 
family’s acceptance of the mortality risk. Guidance and structured processes as identified 
in Donabedian’s Quality of Medical Care model may be warranted.  
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Presently in the SNF setting, there is greater emphasis on obtaining an Advance 
Directive shortly after admission. While this process has improved the understanding of 
patient wishes, it could be expanded upon as part of the care plan process with discussion 
and further exploration of preferences for care direction. Palliative care consideration 
could be explored in that process. Ideally, the subject of palliative care for this population 
should be raised at each care plan conference with the patient and family and updated as 
needed.  
From a patient and family perspective, knowing that their mortality risk is higher 
than their peer group would allow the patient and family to make care and quality of life 
decisions while they are still in control of their destiny. It is not uncommon for the HF 
patient to have an exacerbation of the syndrome forcing hospitalization with inherent 
acute care and treatment without having previous discussions and decisions regarding end 
of life care. With additional mortality risk information provided, having an advance 
directive discussion that considers this mortality risk would benefit care providers and 
ultimately the patients needing acute treatment.  
Methodological, Theoretical, and/or Statistical Importance of the Findings  
 
The approach to the present study was from a positivist framework and uses 
observable data allowing its end product to be generalized (Remenyi et al., 1998). While 
this researcher may have had biases towards the predicted results, objective reality held 
this researcher’s personal biases in check during the process of evaluating the 
phenomenon. As these predictive variables have been obtained utilizing survival analysis, 
they have statistical value as credible factors predicting increased mortality risk. The 
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variables have been used in other risk models that have been tested in the community 
setting. However, not all selected variables were found to be significant. 
Methodologically, survival analysis was the most logical approach to analyze 
retrospective data to determine a predictive set of variables. Statistically, five predictive 
variables were significant in demonstrating a higher risk if the patient had one or more of 
these present in their assessment. With a sample size of greater than 3000 patients from 
24 SNFs across both urban and rural settings, the results are generizable to the SNF 
setting across the United States. As there are no known existing processes to use the RAI-
MDS 3.0 instrument for the purpose of providing end-of-life care, there is value in the 
findings to enable the creation of a mortality HF risk model.  
Clinical Significance of the Findings 
 Future development of a HF mortality risk model utilizing the predictive 
variables is clinically valuable allowing candid conversations with patients entering SNFs 
across the country. This discussion, as noted in the literature, and from this researcher’s 
professional perspective, rarely occurs prior to admission and often not in the SNF setting 
until a patient declines to obvious palliative care criteria. There has been recent 
improvement in SNFs to intiate conversations to obtain an advance directive shortly after 
admission. Having a viable risk model emanating directly from the RAI-MDS 3.0 
assessment would enhance clinical care and seek to improve a patient’s quality of life. 
Once a patient’s end of life care preferences are known, there is potential to reduce 
hospital admissions allowing the patient to remain in the SNF for comfort care rather than 
have aggressive acute care that may or may not improve their quality of life or impact 
their mortality. Patient preferences discussed with their families being present and 
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engaged, if inclusion is desired by the patient, would improve the alignment of goals and 
assist the nursing care team to support the patient and family as the HF syndrome 
progresses. 
Relationship between the Findings, Previous Research, and the 
Theoretical/Conceptual Framework/Model  
 
  This study was framed using Donnabedian’s quality of care framework (2005) 
incorporating both Moorehouse and Mallery’s PATH model (2012) and Kolcaba’s 
Comfort Theory (2003). Each of these frameworks proved valuable in guiding this study. 
Donnabedian’s structure, process, and outcome framework was used to guide the 
evaluation of these variables. From a structure perspective, the patient assessment process 
using the RAI-MDS 3.0 instrument is already in place in the SNF setting. Incorporating a 
future developed model and tool using the predictive variables will allow identification of 
increased mortality risk in those HF patients whose assessment includes positive 
responses of the predictive variables. From an outcome perspective, discussion with the 
patient and family will be fostered with newly identified information guiding the nursing 
process. Moorhouse and Mallery’s PATH framework (2012) is incorporated in this 
discussion of clearly assessing each patient and having forthcoming conversations with 
the patient, family, and the rest of the care team. Providing a palliative care discussion 
will allow the clinical team to provide comfort both physically and emotionally to 
support the patient as their health deteriorates in synchronization with their preferences as 
espoused by Kolcaba (2003) and Moorhouse and Mallery (2012). 
  While substantial research has been conducted to develop predictive HF mortality 
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models, none of these models have been developed specifically for the SNF setting. Each 
of these mortality risk models used similar and sometimes different predictive variables. 
Most of the data regarding these variables are not readily accessible in the SNF setting 
without further clinical testing or data extraction from an acute medical record. Ideally, 
when and if Electronic Health Records are shared among health care settings, the 
potential to incorporate other variables increases. Having a model that is derived directly 
from the RAI- MDS 3.0 assessment will streamline the nursing process, eliminate the 
hesitancy to evaluate the risk, and allow palliative care discussion to occur.   
Implications of the Research for Nursing Practice, Education, and Research 
 
 
  While the nursing profession is improving efforts to engage in palliative care 
discussion with patients and families, a continued focus must occur. As there are various 
mortality risk models available, they are not utilized in most practice settings including 
acute care nor SNFs. Creation of an easy to use risk model can improve nursing practice 
over time as systemic processes become ingrained facilitating holistic care.  
  As identified in this study, there are variables contained in the RAI-MDS 
instrument that are predictive of increased mortality for HF patients. Mortality risk 
assessment is not present in SNFs and evalution of HF risk and that of other chronic 
diseases would benefit the SNF patient population. COPD and diabetes are common in 
the SNF population and are worth further evaluation. Having other risk models that are 
directly obtained from the RAI- MDS instrument will foster enhanced palliative care 
opportunities and have the potential to improve the quality of life and care for SNF 
patients. 
  Education to support a better understanding of palliative care would benefit the 
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staff in SNFs and other care settings. Some nursing education curriculums now contain 
palliative care content and nurses are becoming more aware of the need to discuss end of 
life preference with patients. Further eduation and systemic processes will benefit and 
enhance these needed discussions.  
 Many of the nurses working in SNFs are licensed practical nurses. As their 
curriculum is focused on performance of nursing tasks, they have had little exposure to 
palliative care in their educational curriculum. While some progress has been made to 
incorporate palliative care education into the nursing curriculum, there is still much to be 
accomplished. Mason et al. (2020) identified that nursing education curriculums at the 
undergraduate and graduate level lack palliative care content. At the graduate nursing 
level, efforts are underway to address improving the knowledge of advance practice 
nurses. The American Association of Colleges of Nursing and the End of Life Nursing 
Education Consortium (2019) recently published a plan to address palliative care for 
graduate nurses in the “Preparing Graduate Nursing Students to Ensure Quality Palliative 
Care for the Seriously Ill & Their Families” (Butler et al, 2019).    
  Further research is needed to identify the most predictive variables of HF 
mortality risk. While this study identified five viable variables, there may be other 
variables that would add value to the  the risk model. Analysis over time of patient 
functional decline is one example that could be extrapolated from the assessment data. As 
the SNF setting has a rich data collection and assessment instrument in place, there may 
be additional variables from other tools that can help quantify that risk and provide more 
meaningful information to nurses and patients in their disease progression. 
Implications for Vulnerability and Vulnerable Populations  
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  Patients with heart failure who reside in SNFs are extremely vulnerable due to 
their diminished functionality and health status. The opporuntity for these patients and 
their families to converse with a health professional about their syndrome and probable 
progression would allow them to process that information and make informed decisions. 
Too often, the prognosis is not discussed, or clearly communicated so the patient and 
family can process it and have a secondary or tertiary discussion to clarify what they 
heard and what they understood. This could be structured using the Moorhouse and 
Mallery PATH model (2012) aligning the patient wishes with the clinical care teams 
support and plan. 
Strengths and Weaknesses or Limitations of the Study 
  A significant strength of this study was that it used a diverse sample of heart 
failure patients residing in SNFs located in rural and urban locations. Due to this large 
sample size of SNF patients, there is enhanced external validity increasing the likelihood 
of generalization to the SNF population as a whole. While a similar RAI-MDS instrument 
is used in Canada, it is not clear that the results could be generalized to those populations 
since their health system is uniquely different than that of the United States. The acuity of 
the Canadian SNF population is lower compared to the United states and they rarely offer 
inpatient physical, occupational, or speech therapy as a means to transition back to the 
community. 
      Conversely, weaknesses or limitations of this study include that the sample was large 
and included a number of variables, this may have influenced the results. While the 
researcher was attempting to include many of the variables identified in prior studies, 
doing so may have weakened the model by diluting the hazard ratio results. Other 
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limitations result from the use of a pre-existing database and the RAI-MDS data was not 
collected specifically to address the particular research questions driving this study and 
data captured represented one snapshot/measurement point. Lastly, the RAI-MDS has 
specific coded responses that were designed to guide care and drive payment models. As 
such, the instrument lacked some key factors that are present on other HF risk models. 
The study results may not be applicable in other settings as the data was derived from 
SNF patients specifically.  
Suggestions for Future Research 
 
Research is needed to evaluate the impact of how a mortality risk tool in a care 
delivery system would improve the understanding of palliative care for SNF nurses and 
benefit the patient. The research questions driving this study could be: Does a mortality 
risk assessment tool increase the use of palliative care in SNFs and improve the patient’s 
quality of life? Does having this information influence a patient and their family in their 
decision making? What is the best method to deliver this information to guide the patient 
and their family in a supportive manner? 
As the literature suggests that rehospitalization is a significant predictor of 
declining health and mortality, evaluating how each hospitalization increases the 
mortality risk would provide greater insight into the predictive value of this factor in the 
SNF setting. Clearly, the frailty of this population and increasing hospitalizations may 
shed light on whether that variable alone or in conjunction with other predictive variables 
could provide nurses with a tool to prompt palliative care discussion. 
Conducting further statistical analysis using just the present study’s predictive 
variables could prove valuable in creating a mortality risk model and ultimately a tool. As 
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the variables are significant in predicting mortality risk, having a tool that is generated 
from the RAI-MDS 3.0 could prove to be an effective approach to prompt nurses to 
initiate palliative care discussions. Once developed and tested in SNFs, determining the 
value and benefit to the patient and family should be studied. Findings from the study can 
also be tested to determine if it improves patient’s quality of life through the initiation of 
of palliative care and end of life decision making. 
Summary  
 
 After identifying potential variables from the literature that can be captured in the 
MDS assessment instrument, this research study evaluated whether selected variables 
would predict increased risk of HF mortality in HF patients residing in SNF. Five of nine 
variables provided clear evidence that the RAI-MDS 3.0 assessment instrument contained 
relevant data that could be useful in development of a HF mortality risk model. As an 
administrator and nurse leader in the post-acute health care setting, identifying methods 
to drive quality outcomes is important and needed. Much of what is performed in a SNF 
setting is routine and dictated by regulatory requirements and guidelines. Any 
opportunity to structure a process that improves quality of care outcomes is desired. This 
aligns with the Donabedian Quality of Medical Care model of designing systems to drive 
the desired outcomes.  
Additional research should be conducted to further test the variables in this model 
and determine the impact of mortality risk prediction in the SNF setting so as to improve 
the possibility of palliative care discussion in that setting. While this study obtained 
evidence of predictive variables, much is needed to further refine how these findings can 
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be used to impact quality of life for patients with heart failure who reside in skilled 
nursing facilities.  
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Appendix A 
 
Table 1: Heart Failure Mortality Risk Variables 
 
 
 
Study 
Variable Senni et 
al.,  2013
Pocock et 
al., 2012
Levy et 
al., 2006
Fonarow 
et al., 
2005
Giamouzis 
et al., 
2011
Ouwerkirk 
et al., 
2014
Betihavas 
et al., 
2015
Zomer 
et al., 
2013
Eapern 
et al., 
2013
Rahimi 
et al., 
2014
Yancy 
et al., 
2013
Murad 
et al., 
2015
Chaudhry 
et al., 
2013
Chyu 
et 
al., 
2013Age X X X X x X X X X X
NYHA functional 
class X X X x X X X X X
Comorbidities X X X X
Gender X X X X X X X
Hypertension X X X X
Kidney dysfunction X X X x X X X X X X
Diabetes X X X x X X X X X
Hospital readmission X X X X X X
Depression X X X X
Dyspnea X X
Anemia X X X
Empirical Report for Study Variables
